Mark Emberton

Q: What Schools Are Affiliated With Mark Emberton

Mark Emberton is affiliated with the following schools: University College London, Royal Postgraduate Medical School, London School of Hygiene and Tropical Medicine

Mark Emberton's AcademicInfluence.com Rankings

Mark Emberton

Medical

#815

World Rank

#1068

Historical Rank

Urology

World Rank

Historical Rank

medical Degrees

Mark Emberton

Philosophy

#4705

World Rank

#7321

Historical Rank

Logic

#2110

World Rank

#3027

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Mark Emberton Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Mark Emberton is a urologist and prostate cancer research specialist using novel imaging techniques and minimally invasive treatments to improve diagnosis and treatment of prostate cancer. Emberton is Professor of Interventional oncology at University College London and Dean of its Faculty of Medical Sciences. and is Honorary Consultant Urological Surgeon at University College Hospital. He serves as Founding Pioneer of the charity Prostate Cancer UK.

(See a Problem?)

Mark Emberton's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study (2017) (2057)
MRI‐Targeted or Standard Biopsy for Prostate‐Cancer Diagnosis (2018) (1661)
EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. (2013) (1119)
Systematic review of complications of prostate biopsy. (2013) (840)
Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. (2011) (740)
Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. (2015) (705)
EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). (2004) (634)
Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. (2013) (564)
Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. (2015) (419)
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. (2013) (413)
How good is MRI at detecting and characterising cancer within the prostate? (2006) (382)
Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study (2012) (377)
The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review (2014) (345)
Is it time to consider a role for MRI before prostate biopsy? (2009) (332)
Characterizing clinically significant prostate cancer using template prostate mapping biopsy. (2011) (294)
Photodynamic therapy for prostate cancer—a review of current status and future promise (2009) (281)
Weakly-supervised convolutional neural networks for multimodal image registration (2018) (272)
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. (2013) (240)
New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. (2017) (232)
Focal therapy for localized prostate cancer: a phase I/II trial. (2011) (228)
Focal Therapy: Patients, Interventions, and Outcomes—A Report from a Consensus Meeting (2015) (226)
Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. (2003) (218)
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. (2017) (216)
The Postoperative Morbidity Survey was validated and used to describe morbidity after major surgery. (2007) (214)
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology (2010) (207)
The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. (1998) (202)
Benign prostatic hyperplasia: a progressive disease of aging men. (2003) (202)
Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery. (2006) (198)
Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer. (2013) (195)
A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer (2018) (192)
Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. (2014) (192)
Photodynamic therapy for prostate cancer recurrence after radiotherapy: a phase I study. (2002) (184)
MR to ultrasound registration for image-guided prostate interventions (2012) (181)
Focal therapy in prostate cancer-report from a consensus panel. (2010) (179)
Multiparametric MR imaging for detection of clinically significant prostate cancer: a validation cohort study with transperineal template prostate mapping as the reference standard. (2013) (177)
Will focal therapy become a standard of care for men with localized prostate cancer? (2007) (167)
Multiparametric MRI for prostate cancer diagnosis: current status and future directions (2019) (161)
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? (2012) (161)
Photodynamic therapy using meso tetra hydroxy phenyl chlorin (mTHPC) in early prostate cancer (2006) (160)
Focal Ablation Targeted to the Index Lesion in Multifocal Localised Prostate Cancer: a Prospective Development Study. (2015) (153)
The effect of prostatectomy on symptom severity and quality of life. (1996) (153)
Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management (2008) (147)
Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway? (2013) (145)
Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment (2004) (144)
The Progression of Benign Prostatic Hyperplasia: Examining the Evidence and Determining the Risk (2001) (141)
Optimising the Diagnosis of Prostate Cancer in the Era of Multiparametric Magnetic Resonance Imaging: A Cost-effectiveness Analysis Based on the Prostate MR Imaging Study (PROMIS) (2018) (140)
TOOKAD® Soluble vascular‐targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer (2013) (139)
Computer‐aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer (2008) (134)
MR imaging of prostate after treatment with high-intensity focused ultrasound. (2008) (134)
The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level—Can it rule out clinically significant prostate cancer? (2014) (132)
The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer (2010) (131)
High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series (2009) (125)
Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review and Meta-analysis. (2019) (124)
INITIAL ASSESSMENT OF SAFETY AND CLINICAL FEASIBILITY OF IRREVERSIBLE ELECTROPORATION IN THE FOCAL TREATMENT OF PROSTATE CANCER (2014) (121)
Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer (2012) (120)
The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta‐analysis (2007) (120)
Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. (2010) (118)
Survival after postoperative morbidity: a longitudinal observational cohort study† (2014) (118)
Acute urinary retention in men: an age old problem (1999) (116)
Self-management for men with lower urinary tract symptoms (2006) (114)
Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer (2012) (110)
Performance of multiparametric MRI in men at risk of prostate cancer before the first biopsy: a paired validating cohort study using template prostate mapping biopsies as the reference standard (2013) (108)
Trends in paediatric circumcision and its complications in England between 1997 and 2003 (2006) (108)
Label-driven weakly-supervised learning for multimodal deformarle image registration (2017) (106)
The accuracy of transrectal ultrasonography supplemented with computer‐aided ultrasonography for detecting small prostate cancers (2008) (103)
The feasibility and safety of high‐intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy (2008) (101)
Minimally-invasive technologies in uro-oncology: the role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer. (2009) (100)
The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy (2017) (97)
Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial. (2020) (97)
Alfuzosin 10 mg once daily improves sexual function in men with lower urinary tract symptoms and concomitant sexual dysfunction (2005) (96)
A systematic review and critique of the literature relating hospital or surgeon volume to health outcomes for 3 urological cancer procedures. (2004) (95)
A biopsy simulation study to assess the accuracy of several transrectal ultrasonography (TRUS)‐biopsy strategies compared with template prostate mapping biopsies in patients who have undergone radical prostatectomy (2012) (94)
Guidelines on the Management of Male Lower Urinary Tract Symptoms ( LUTS ) , incl . Benign Prostatic Obstruction (2012) (91)
PROMIS — Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer☆ (2015) (90)
Identifying candidates for active surveillance: an evaluation of the repeat biopsy strategy for men with favorable risk prostate cancer. (2012) (88)
Acute urinary retention (2000) (87)
Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy (2012) (86)
Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11‐vascular‐targeted photodynamic (VTP) therapy (2015) (85)
Detection, localisation and characterisation of prostate cancer by Prostate HistoScanning™ (2012) (85)
Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy (2010) (84)
Medium‐term oncological outcomes in a large cohort of men treated with either focal or hemi‐ablation using high‐intensity focused ultrasonography for primary localized prostate cancer (2019) (82)
Guidelines on Benign Prostatic Hyperplasia (2006) (82)
The National Prostatectomy Audit: the clinical management of patients during hospital admission. (1995) (82)
Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. (2004) (80)
The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation. (2012) (80)
TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer (2015) (78)
Catheter‐associated urinary tract infections: prevalence of uropathogens and pattern of antimicrobial resistance in a UK hospital (1996–2001) (2003) (76)
Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. (2018) (75)
Can we deliver randomized trials of focal therapy in prostate cancer? (2014) (74)
A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study (2013) (73)
A description of radical nephrectomy practice and outcomes in England: 1995–2002 (2005) (73)
The patient's dilemma: prostate cancer treatment choices. (2003) (72)
A novel tissue engineered three-dimensional in vitro colorectal cancer model☆ (2013) (72)
Early detection of cancer (2022) (70)
Management of low risk prostate cancer: active surveillance and focal therapy (2014) (69)
Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey (2007) (69)
A systematic review of the reliability of frequency‐volume charts in urological research and its implications for the optimum chart duration (2007) (69)
“Textural analysis of multiparametric MRI detects transition zone prostate cancer” (2016) (69)
Five-year Outcomes of Magnetic Resonance Imaging–based Active Surveillance for Prostate Cancer: A Large Cohort Study☆ (2020) (68)
To what extent does the prostate‐specific antigen nadir predict subsequent treatment failure after transrectal high‐intensity focused ultrasound therapy for presumed localized adenocarcinoma of the prostate? (2006) (68)
Handbook of Nanophysics (2010) (68)
Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer. (2017) (67)
Quantitative tissue analyses of prostate cancer foci in an unselected cystoprostatectomy series (2012) (65)
Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer (2017) (65)
Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness (2018) (65)
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3‐year experience in real‐life practice (2008) (64)
Incidence of primary and recurrent acute urinary retention between 1998 and 2003 in England. (2006) (64)
“TREXIT 2020”: why the time to abandon transrectal prostate biopsy starts now (2020) (64)
Adversarial Deformation Regularization for Training Image Registration Neural Networks (2018) (63)
The fear of prostate cancer in men with lower urinary tract symptoms: should symptomatic men be screened? (2003) (63)
Mortality in men admitted to hospital with acute urinary retention: database analysis (2007) (63)
Multi-Parametric Magnetic Resonance Imaging to Rule-In and Rule-Out Clinically Important Prostate Cancer in Men at Risk: A Cohort Study (2011) (63)
A review of guidelines on benign prostatic hyperplasia and lower urinary tract symptoms: are all guidelines the same? (2003) (62)
Whole‐gland salvage high‐intensity focused ultrasound therapy for localized prostate cancer recurrence after external beam radiation therapy (2012) (61)
Focal Therapy for Prostate Cancer: Rationale and Treatment Opportunities (2013) (61)
Modelling Prostate Motion for Data Fusion During Image-Guided Interventions (2011) (61)
Usefulness of prostate‐specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study (2012) (61)
Men's experiences of having lower urinary tract symptoms: factors relating to bother (2004) (61)
Prostate Cancer Risk Inflation as a Consequence of Image-targeted Biopsy of the Prostate: A Computer Simulation Study (2014) (60)
Magnetic resonance imaging targeted transperineal prostate biopsy: a local anaesthetic approach (2017) (59)
Epithelializing stent for benign prostatic hyperplasia: a systematic review of the literature. (2007) (59)
5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery. (2004) (59)
Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort. (2016) (58)
The Reten‐World survey of the management of acute urinary retention: preliminary results (2008) (58)
MRI-targeted prostate biopsy: a review of technique and results (2013) (58)
Visually directed high‐intensity focused ultrasound for organ‐confined prostate cancer: a proposed standard for the conduct of therapy (2006) (57)
A prospective development study investigating focal irreversible electroporation in men with localised prostate cancer: Nanoknife Electroporation Ablation Trial (NEAT) (2014) (57)
The beneficial effect of alfuzosin 10 mg once daily in ‘real‐life’ practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation (2006) (57)
The impact of self‐management of lower urinary tract symptoms on frequency‐volume chart measures (2009) (57)
Engineering a vascularised 3D in vitro model of cancer progression (2017) (56)
Patient Reported Outcome Measures for Transperineal Template Prostate Mapping Biopsies in the PICTURE Study (2018) (55)
Multiparametric MRI for detection of radiorecurrent prostate cancer: added value of apparent diffusion coefficient maps and dynamic contrast-enhanced images (2015) (54)
Photodynamic therapy for focal ablation of the prostate (2010) (54)
The SmartTarget Biopsy Trial: A Prospective, Within-person Randomised, Blinded Trial Comparing the Accuracy of Visual-registration and Magnetic Resonance Imaging/Ultrasound Image-fusion Targeted Biopsies for Prostate Cancer Risk Stratification (2019) (54)
Image-directed, tissue-preserving focal therapy of prostate cancer: a feasibility study of a novel deformable magnetic resonance-ultrasound (MR-US) registration system (2013) (53)
The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials. (2016) (53)
The thermo‐expandable metallic stent for managing benign prostatic hyperplasia: a systematic review (2006) (53)
Variation in outcome of surgical procedures (1994) (53)
Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. (2019) (52)
Men and Chronic Illness: A Qualitative Study of LUTS (2004) (52)
The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management (2005) (52)
The role of MRI in active surveillance of prostate cancer (2013) (52)
The PICTURE study -- prostate imaging (multi-parametric MRI and Prostate HistoScanning™) compared to transperineal ultrasound guided biopsy for significant prostate cancer risk evaluation. (2014) (52)
A computer generated interactive transurethral prostatic resection simulator. (1999) (52)
Visually directed vs. software-based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer. (2015) (51)
Active surveillance and radical therapy in prostate cancer: can focal therapy offer the middle way? (2008) (51)
Comparison of patients' needs for information on prostate surgery with printed materials provided by surgeons. (1995) (51)
What Type of Prostate Cancer Is Systematically Overlooked by Multiparametric Magnetic Resonance Imaging? An Analysis from the PROMIS Cohort (2020) (51)
Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4‐year results of the CombAT study (2014) (51)
New directions in information for patients (1995) (50)
Prostate Cancer Tumour Features on Template Prostate-mapping Biopsies: Implications for Focal Therapy☆ (2014) (49)
Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials (2008) (49)
Hospital admissions after transrectal ultrasound‐guided biopsy of the prostate in men diagnosed with prostate cancer: A database analysis in England (2015) (49)
Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study (2019) (47)
Prostatic cancer surveillance following whole-gland high-intensity focused ultrasound: comparison of MRI and prostate-specific antigen for detection of residual or recurrent disease. (2012) (47)
Long‐term efficacy and safety of alfuzosin 10 mg once daily: a 2‐year experience in ‘real‐life’ practice (2006) (46)
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters (2017) (46)
THE ROLE OF MAGNETIC RESONANCE IMAGING IN TARGETING PROSTATE CANCER IN PATIENTS WITH PREVIOUS NEGATIVE BIOPSIES AND ELEVATED PROSTATE‐SPECIFIC ANTIGEN LEVELS (2009) (46)
Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States. (2016) (45)
VERDICT MRI for Prostate Cancer: Intracellular Volume Fraction versus Apparent Diffusion Coefficient (2019) (45)
Guidelines on the Treatment of Non-neurogenic Male LUTS (2011) (45)
The ‘top 10’ urological procedures: a study of hospital episodes statistics 1998–99 (2002) (44)
Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction (2010) (43)
Accuracy of Transperineal Targeted Prostate Biopsies, Visual Estimation and Image Fusion in Men Needing Repeat Biopsy in the PICTURE Trial (2018) (43)
Rectal fistulae after salvage high‐intensity focused ultrasound for recurrent prostate cancer after combined brachytherapy and external beam radiotherapy (2009) (43)
Logistic regression model for diagnosis of transition zone prostate cancer on multi-parametric MRI (2014) (42)
Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials). (2019) (42)
Inter-site Variability in Prostate Segmentation Accuracy Using Deep Learning (2018) (42)
Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: a consensus approach. (2004) (42)
The relationship between objective frequency-volume chart data and the I-PSS in men with lower urinary tract symptoms. (2007) (41)
Automatic segmentation of prostate MRI using convolutional neural networks: Investigating the impact of network architecture on the accuracy of volume measurement and MRI-ultrasound registration (2019) (41)
MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years (2018) (40)
Guidelines on Conservative Treatment of Non-neurogenic Male LUTS (2010) (39)
Multiparametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis (2014) (38)
The influence of family history on prostate cancer risk: implications for clinical management (2011) (38)
Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: A prospective development study. (2017) (38)
Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk (2007) (38)
Do we do what they say we do? Coding errors in urology (2000) (37)
INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer (2016) (37)
Stiffness memory of indirectly 3D-printed elastomer nanohybrid regulates chondrogenesis and osteogenesis of human mesenchymal stem cells. (2018) (37)
Morbidity associated with primary high intensity focused ultrasound and redo high intensity focused ultrasound for localized prostate cancer. (2014) (36)
Does photodynamic therapy have the necessary attributes to become a future treatment for organ‐confined prostate cancer? (2005) (36)
MRI in active surveillance: a critical review (2018) (36)
MR to Ultrasound Image Registration for Guiding Prostate Biopsy and Interventions (2009) (36)
Zone-specific logistic regression models improve classification of prostate cancer on multi-parametric MRI (2015) (35)
Conceptual basis for focal therapy in prostate cancer. (2010) (35)
Focal salvage high‐intensity focused ultrasound in radiorecurrent prostate cancer (2017) (34)
Population-based prediction of subject-specific prostate deformation for MR-to-ultrasound image registration (2015) (34)
Photodynamic therapy for prostate cancer—an emerging approach for organ‐confined disease (2011) (33)
Definition of at‐risk patients: dynamic variables (2006) (33)
Management of low risk prostate cancer—active surveillance and focal therapy (2014) (33)
Dosimetry Modeling for Focal Low-Dose-Rate Prostate Brachytherapy. (2014) (33)
Active surveillance for low-risk prostate cancer. (2013) (33)
Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway☆ (2013) (32)
Histological outcomes after focal high-intensity focused ultrasound and cryotherapy (2015) (32)
Prostate Indeterminate Lesions on Magnetic Resonance Imaging-Biopsy Versus Surveillance: A Literature Review. (2019) (31)
A Statistical Motion Model Based on Biomechanical Simulations for Data Fusion during Image-Guided Prostate Interventions (2008) (31)
Risk stratification for benign prostatic hyperplasia (BPH) treatment (2011) (31)
Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. (2005) (31)
The Evolution of MRI of the Prostate: The Past, the Present, and the Future. (2019) (30)
Multiparametric prostate MRI: technical conduct, standardized report and clinical use. (2017) (30)
Can multiparametric magnetic resonance imaging predict upgrading of transrectal ultrasound biopsy results at more definitive histology? (2014) (30)
A biomedical engineering approach to mitigate the errors of prostate biopsy (2012) (30)
Can MRI replace serial biopsies in men on active surveillance for prostate cancer? (2014) (29)
The FORECAST study - Focal recurrent assessment and salvage treatment for radiorecurrent prostate cancer. (2015) (29)
Salvage Local Treatments After Focal Therapy for Prostate Cancer. (2019) (29)
3D Cancer Models: The Need for a Complex Stroma, Compartmentalization and Stiffness (2021) (29)
Changing trends in the management of phaeochromocytoma (1998) (28)
Lifestyle and behavioural interventions for men on watchful waiting with uncomplicated lower urinary tract symptoms: a national multidisciplinary survey (2003) (28)
Novel approaches to improve prostate cancer diagnosis and management in early‐stage disease (2012) (28)
First-in-human in vivo non-invasive assessment of intra-tumoral metabolic heterogeneity in renal cell carcinoma (2019) (28)
Transperineal template prostate‐mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer (2016) (27)
Antibiotics on urethral catheter withdrawal: a hit and miss affair. (2004) (27)
Impact of non-response and of late-response by patients in a multi-centre surgical outcome audit. (1995) (26)
The Prevalence of Clinically Significant Prostate Cancer According to Commonly Used Histological Thresholds in Men Undergoing Template Prostate Mapping Biopsies. (2016) (26)
The next level of 3D tumour models: immunocompetence. (2016) (26)
Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort (2020) (26)
A 3D In Vitro Cancer Model as a Platform for Nanoparticle Uptake and Imaging Investigations (2014) (26)
Multiparametric Magnetic Resonance Imaging in the Management and Diagnosis of Prostate Cancer: Current Applications and Strategies (2014) (26)
Confirmatory Factor Analysis of the Subjective Exercise Experiences Scale among Children (1997) (26)
Role of α-Blockers in Type III Prostatitis: A Systematic Review of the Literature (2007) (26)
Role of MRI in planning radical prostatectomy: what is the added value? (2019) (24)
MRI findings in men on active surveillance for prostate cancer: does dutasteride make MRI visible lesions less conspicuous? Results from a placebo-controlled, randomised clinical trial (2017) (24)
The Hallmarks of BPH Progression and Risk Factors (2003) (24)
The PROMIS study: A paired-cohort, blinded confirmatory study evaluating the accuracy of multi-parametric MRI and TRUS biopsy in men with an elevated PSA. (2016) (24)
Focal therapy in prostate cancer: determinants of success and failure. (2010) (24)
Comparison of MRI- and TRUS-Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy-Naive Men: A Systematic Review and Meta-Analysis. (2020) (23)
Focal therapy will become a standard option for selected men with localized prostate cancer. (2014) (23)
Sonablate®-500: transrectal high-intensity focused ultrasound for the treatment of prostate cancer (2006) (23)
Salvage high-intensity focused ultrasound for patients with recurrent prostate cancer after brachytherapy. (2014) (23)
A pilot randomized double‐blind placebo‐controlled trial on the use of antibiotics on urinary catheter removal to reduce the rate of urinary tract infection: the pitfalls of ciprofloxacin (2004) (23)
Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients: physiological distribution, statistical differences, imaging pearls, and normal variants (2015) (23)
Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer (2021) (23)
Low Urinary Tract. Lower urinary tract symptoms in men: self‐perceptions and the concept of bother (2005) (23)
Is focal therapy the future for prostate cancer? (2010) (23)
Changes in patient characteristics and outcomes for radical cystectomy in England (2005) (22)
MRI-Targeted Biopsy for Prostate-Cancer Diagnosis. (2018) (22)
MAPPED study design: a 6 month randomised controlled study to evaluate the effect of dutasteride on prostate cancer volume using magnetic resonance imaging. (2013) (22)
Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate (2015) (22)
Recollected versus contemporary patient reports of pre-operative symptoms in men undergoing transurethral prostatic resection for benign disease. (1995) (22)
Evaluating the Trade-offs Men with Localised Prostate Cancer Make Between the Risks and Benefits of Treatments: The COMPARE Study. (2020) (22)
The effect of neoadjuvant androgen suppression on prostate cancer‐related outcomes after high‐intensity focused ultrasound therapy (2006) (22)
The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED—A Randomized, Placebo Controlled, Double‐Blind Clinical Trial (2017) (21)
Investigating the performance of a novel pH and cathepsin B sensitive, stimulus-responsive nanoparticle for optimised sonodynamic therapy in prostate cancer (2020) (21)
Cancer invasion regulates vascular complexity in a three-dimensional biomimetic model. (2019) (21)
Understanding PI-QUAL for prostate MRI quality: a practical primer for radiologists (2021) (21)
Benchmarks for success in focal therapy of prostate cancer: cure or control? (2010) (21)
Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study. (2020) (21)
Stiffness memory nanohybrid scaffolds generated by indirect 3D printing for biologically responsive soft implants. (2018) (20)
Classic papers in Urology. (1999) (20)
Does true Gleason pattern 3 merit its cancer descriptor? (2016) (20)
Transperineal Magnetic Resonance Imaging-targeted Biopsy versus Transperineal Template Prostate Mapping Biopsy in the Detection of Localised Radio-recurrent Prostate Cancer. (2016) (20)
Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study (2020) (20)
Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer. (2016) (20)
The role of the multiparametric MRI in the diagnosis of prostate cancer in biopsy-naïve men (2017) (20)
Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis (2020) (19)
Point-of-care PSA testing: an evaluation of PSAwatch (2007) (19)
Threshold volumes for urological cancer surgery: a survey of UK urologists (2004) (19)
A comparison of Bayesian and non-linear regression methods for robust estimation of pharmacokinetics in DCE-MRI and how it affects cancer diagnosis (2017) (19)
Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma (2020) (19)
Light penetration in the human prostate: a whole prostate clinical study at 763 nm. (2011) (19)
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily. (2006) (19)
A comparison of the accuracy of statistical models of prostate motion trained using data from biomechanical simulations. (2010) (18)
Role of focal salvage ablative therapy in localised radiorecurrent prostate cancer (2013) (18)
experiment choice non-metastatic prostate cancer: discrete Patients' preferences for the management of (2004) (18)
Prostate cancer heterogeneity: texture analysis score based on multiple magnetic resonance imaging sequences for detection, stratification and selection of lesions at time of biopsy (2019) (18)
Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma (2019) (18)
A comparison of time taken to return to baseline erectile function following focal and whole gland ablative therapies for localized prostate cancer: A systematic review. (2017) (18)
European Association of Urology GUIDELINES ON BENIGN PROSTATIC HYPERPLASIA (2001) (18)
Cellular responses to thermoresponsive stiffness memory elastomer nanohybrid scaffolds by 3D-TIPS. (2019) (18)
A review of economic evaluations of diagnostic strategies using imaging in men at risk of prostate cancer (2015) (18)
Evaluation of functional outcomes after a second focal high‐intensity focused ultrasonography (HIFU) procedure in men with primary localized, non‐metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry (2020) (17)
A Modified Newcastle-Ottawa Scale for Assessment of Study Quality in Genetic Urological Research. (2020) (17)
Biopsy strategies for selecting patients for focal therapy for prostate cancer (2014) (17)
Case report. Bile duct injury following laparoscopic cholecystectomy (1992) (17)
A rare tumour in the pelvis presenting with lower urinary symptoms: 'sclerosing epithelioid fibrosarcoma'. (2001) (17)
Prostate cancer diagnostic pathway: Is a one-stop cognitive MRI targeted biopsy service a realistic goal in everyday practice? A pilot cohort in a tertiary referral centre in the UK (2018) (16)
Self-management for men with lower urinary tract symptoms (2009) (16)
225 Management of acute urinary retention (AUR) in patients with BPH: A worldwide comparison (2004) (16)
Development and Phantom Validation of a 3-D-Ultrasound-Guided System for Targeting MRI-Visible Lesions During Transrectal Prostate Biopsy (2017) (16)
What tumours should we treat with focal therapy based on risk category, grade, size and location? (2015) (16)
Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial. (2020) (16)
The reliability of the frequency‐volume chart in assessing lower urinary tract symptoms (2007) (16)
Conditional Segmentation in Lieu of Image Registration (2019) (15)
Identifying the index lesion with template prostate mapping biopsies. (2015) (15)
False Positive Multiparametric Magnetic Resonance Imaging Phenotypes in the Biopsy-naïve Prostate: Are They Distinct from Significant Cancer-associated Lesions? Lessons from PROMIS☆ (2020) (15)
Outpatient follow up (1995) (15)
A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol (2017) (15)
Inter-reader agreement of the PI-QUAL score for prostate MRI quality in the NeuroSAFE PROOF trial (2021) (15)
PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure (2016) (14)
BPH: Social Impact and Patient's Perspective (2006) (14)
Modernising Care for Patients Undergoing Major Surgery: Improving Patient Outcomes & Increasing Clinical Efficiency. A report by the Improving Surgical Outcomes Group 2005. (2005) (14)
Focal HIFU therapy for anterior compared to posterior prostate cancer lesions (2020) (14)
Intraoperative Organ Motion Models with an Ensemble of Conditional Generative Adversarial Networks (2017) (14)
A Dedicated Prostate MRI Teaching Course Improves the Ability of the Urologist to Interpret Clinically Significant Prostate Cancer on Multiparametric MRI. (2019) (14)
Protocol for a feasibility study of a cohort embedded randomised controlled trial comparing NEphron Sparing Treatment (NEST) for small renal masses (2019) (14)
Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study (2019) (14)
Has magnetic resonance-guided biopsy of the prostate become the standard of care? (2013) (14)
MRI/TRUS fusion software-based targeted biopsy: the new standard of care? (2015) (14)
The British Urology Researchers in Surgical Training (BURST) Research Collaborative: an alternative research model for carrying out large scale multi‐centre urological studies (2018) (14)
Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results (2019) (14)
Multiparametric ultrasound versus multiparametric MRI to diagnose prostate cancer (CADMUS): a prospective, multicentre, paired-cohort, confirmatory study. (2022) (13)
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. (2006) (13)
Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer (2018) (13)
The "Is mpMRI Enough" or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy. (2020) (13)
Focal Therapy of Prostate Cancer Using Irreversible Electroporation. (2015) (13)
Optimization of prostate biopsy - Micro-Ultrasound versus MRI (OPTIMUM): A 3-arm randomized controlled trial evaluating the role of 29 MHz micro-ultrasound in guiding prostate biopsy in men with clinical suspicion of prostate cancer. (2021) (12)
Targeted biopsy of the prostate: does this result in improvement in detection of high‐grade cancer or the occurrence of the Will Rogers phenomenon? (2019) (12)
The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series. (2020) (12)
Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. (2022) (12)
PSA Criteria to Diagnose Failure of Cancer Control following Focal Therapy for Non-metastatic Prostate Cancer Using High Intensity Focused Ultrasound. (2020) (12)
An analysis of the Research Fellowship Scheme of the Royal College of Surgeons of England. (2005) (12)
Prostate cancer detection using quantitative T2 and T2‐weighted imaging: The effects of 5‐alpha‐reductase inhibitors in men on active surveillance (2018) (12)
Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis (2020) (12)
Prostate MRI quality: a critical review of the last 5 years and the role of the PI-QUAL score (2021) (12)
936 TOOKAD ® SOLUBLE (PADELIPORFIN) SECOND GENERATION VASCULAR TARGETED PHOTODYNAMIC THERAPY (VTP) FOR PROSTATE CANCER: SAFETY AND FEASIBILITY (2010) (12)
Update on multiparametric prostate MRI during active surveillance: current and future trends and role of the PRECISE recommendations. (2020) (12)
Repeat Prostate Biopsy: Rationale, Indications, and Strategies. (2015) (12)
The natural history of prostate cancer on MRI: lessons from an active surveillance cohort (2018) (12)
86 RESULTS OF TOOKAD® SOLUBLE VASCULAR TARGETED PHOTODYNAMIC THERAPY (VTP) FOR LOW RISK LOCALIZED PROSTATE CANCER (PCM201/PCM203) (2011) (12)
ASA scores in the preoperative patient: feedback to clinicians can improve data quality. (2007) (12)
Sequential prostate MRI reporting in men on active surveillance: initial experience of a dedicated PRECISE software program. (2019) (12)
Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy. (2016) (11)
Focal therapy for prostate cancer: fact or fiction? (2010) (11)
Role of magnetic resonance imaging in defining a biopsy strategy for detection of prostate cancer (2014) (11)
Development and internal validation of prediction models for biochemical failure and composite failure after focal salvage high intensity focused ultrasound for local radiorecurrent prostate cancer: Presentation of risk scores for individual patient prognoses. (2018) (11)
Retrieving semen from a dead patient. (1998) (11)
Management of Radiologically Indeterminate Magnetic Resonance Imaging Signals in Men at Risk of Prostate Cancer. (2017) (11)
Health technology assessment in evolution – focal therapy in localised prostate cancer (2014) (11)
Re: Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. (2008) (11)
An evaluation of irreversible electroporation thresholds in human prostate cancer and potential correlations to physiological measurements (2017) (11)
Role of alpha-blockers in type III prostatitis: a systematic review of the literature. (2007) (11)
Cellular senescence as a possible link between prostate diseases of the ageing male (2021) (11)
Role of repeated prostatic massage in chronic prostatitis: a systematic review of the literature. (2008) (11)
Alfuzosin 10MG once daily improves sexual function in men with luts and concomitant sexual dysfunction (2003) (10)
Modelling Prostate Gland Motion for Image-Guided Interventions (2008) (10)
Diagnostic accuracy of flow rate testing in urology (2003) (10)
Could self-management challenge pharmacotherapy as a long-term treatment for uncomplicated lower urinary tract symptoms? (2004) (10)
High-Intensity-Focused Ultrasound for Prostate Cancer (2021) (10)
Thermoresponsive Stiffness Softening of Hierarchically Porous Nanohybrid Membranes Promotes Niches for Mesenchymal Stem Cell Differentiation (2019) (10)
Re: Giacomo Novara, Antonio Galfano, Vincenzo Ficarra and Walter Artibani. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur urol 2006;50:675-83. (2007) (10)
Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer (2018) (10)
Methodological considerations in assessing the utility of imaging in early prostate cancer (2015) (10)
Focal therapy for prostate cancer: a potential strategy to address the problem of overtreatment. (2010) (10)
The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial (2016) (10)
The CADMUS trial - Multi-parametric ultrasound targeted biopsies compared to multi-parametric MRI targeted biopsies in the diagnosis of clinically significant prostate cancer. (2017) (10)
Towards a minimum dataset in urology (2000) (10)
Prostate Imaging Compared to Transperineal Ultrasound-guided biopsy for significant prostate cancer Risk Evaluation (PICTURE): a prospective cohort validating study assessing Prostate HistoScanning (2018) (10)
Is prostate magnetic resonance imaging going to break the bank? (2014) (9)
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array (2016) (9)
Prediction of significant prostate cancer in biopsy-naïve men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS (2019) (9)
Human airway-like multilayered tissue on 3D-TIPS printed thermoresponsive elastomer/collagen hybrid scaffolds. (2020) (9)
An algorithm for managing the failure of external beam radiotherapy in prostate cancer (2007) (9)
Why Focal Therapy is a Legitimate and Necessary Response to a Changing World. (2015) (9)
The volume outcome relationship in surgery (2004) (9)
Prostate Radiofrequency Focal Ablation (ProRAFT) Trial: A Prospective Development Study Evaluating a Bipolar Radiofrequency Device to Treat Prostate Cancer. (2020) (9)
Prostate cancer treated with irreversible electroporation: MRI-based volumetric analysis and oncological outcome. (2019) (9)
Association Between Multiparametric Magnetic Resonance Imaging of the Prostate and Oncological Outcomes after Primary Treatment for Prostate Cancer: A Systematic Review and Meta-analysis. (2020) (9)
Is it time to reconsider the role of prostatic inflammation in the pathogenesis of lower urinary tract symptoms? (2005) (9)
Patient-led Management of BPH: From Watchful Waiting to Self-management of LUTS (2006) (9)
Delayed presentation of intestinal atresia and intussusception--a case report and literature review. (1993) (9)
Immunohistochemical biomarker validation in highly selective needle biopsy microarrays derived from mpMRI‐characterized prostates (2018) (9)
Magnetic Resonance Imaging Should Be Used in the Active Surveillance of Patients with Localised Prostate Cancer. (2019) (9)
SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men (2007) (9)
DWI and PRECISE criteria in men on active surveillance for prostate cancer: A multicentre preliminary experience of different ADC calculations. (2019) (9)
Focal Therapy in Prostate Cancer (2012) (9)
1788 RESULTS OF TOOKAD® SOLUBLE VASCULAR TARGETED PHOTODYNAMIC THERAPY (VTP) FOR LOW RISK LOCALIZED PROSTATE CANCER (PCM203) (2011) (9)
Comparative audit: a new method of delivering audit. (1991) (9)
1643: Long-Term Safety and Improvement on LUTS, Quality of Life and Sexual Function with Alfuzosin 10mg Once Daily: A 3-Year Experience in BPH Patients in Real Life Practice (2006) (8)
Technical Note: Error metrics for estimating the accuracy of needle/instrument placement during transperineal magnetic resonance/ultrasound‐guided prostate interventions (2018) (8)
Utilization of focal therapy for patients discontinuing active surveillance of prostate cancer: Recommendations of an international Delphi consensus. (2021) (8)
Multiparametric prostate MRI quality assessment using a semi-automated PI-QUAL software program (2021) (8)
Early repair of inguinal hernia in preterm infants with oxygen‐dependent bronchopulmonary dysplasia (1996) (8)
Single application of high‐intensity focused ultrasound as a first‐line therapy for clinically localized prostate cancer: 5‐year outcomes (2012) (8)
The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer. (2014) (8)
SCREENING FOR PROSTATE CANCER APPEARS TO WORK, BUT AT WHAT COST? (2009) (8)
584 Early clinical experience of focal therapy for localised prostate cancer using irreversible electroporation (2013) (7)
What value is the patient's experience of surgery to surgeons?: the merits and demerits of patient satisfaction surveys. (1993) (7)
Self-management in lower urinary tract symptoms: the next major therapeutic revolution (2006) (7)
Active surveillance: is there a need for better risk stratification at the outset? (2010) (7)
The anti-angiogenic tyrosine kinase inhibitor Pazopanib kills cancer cells and disrupts endothelial networks in biomimetic three-dimensional renal tumouroids (2020) (7)
From computer-assisted intervention research to clinical impact: The need for a holistic approach (2016) (7)
Is a negative prostate biopsy a risk factor for a prostate cancer related death? (2017) (7)
Clinical practice guidelines for the surgeon—how should they be understood and applied? (2001) (7)
The role of anticholinergic drugs in men with lower urinary tract symptoms (2008) (7)
Surgery, drugs, and the male orgasm (1997) (7)
The feasibility and cost of a large multicentre audit of process and outcome of prostatectomy. (1995) (7)
Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control (2021) (7)
Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stock (2020) (7)
Computer-aided diagnosis of prostate cancer using multiparametric MRI and clinical features: A patient-level classification framework (2021) (7)
Defining the level of evidence for technology adoption in the localized prostate cancer pathway (2014) (7)
The Use of a Structured Form during Urology Out-patient Consultations (2005) (7)
EUROPEAN ASSOCIATION OF UROLOGY (2004) (7)
A novel randomised controlled trial design in prostate cancer (2015) (7)
1096 The natural history of untreated prostate MRI lesions in an active surveillance prostate cancer population – 260 patient-years (2012) (7)
Evaluation of PSA and PSA Density in a Multiparametric Magnetic Resonance Imaging-Directed Diagnostic Pathway for Suspected Prostate Cancer: The INNOVATE Trial (2021) (7)
To what extent do real life practice studies differ from randomized controlled trials in lower urinary tract symptoms/benign prostatic hyperplasia? (2006) (7)
Sexual dysfunction in 3,230 men with luts suggestive of BPH in Europe, Russia, Middle-East, Latin America and Asia (2003) (7)
Image‐Guided Magnetic Thermoseed Navigation and Tumor Ablation Using a Magnetic Resonance Imaging System (2022) (6)
[International comparison of guidelines for the management of benign prostatic hyperplasia: use of a validated generic tool]. (2004) (6)
Added value of diffusion‐weighted images and dynamic contrast enhancement in multiparametric magnetic resonance imaging for the detection of clinically significant prostate cancer in the PICTURE trial (2019) (6)
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer - Authors' reply. (2017) (6)
Exploring the risk-reward balance in focal therapy for prostate cancer—a contribution to the debate (2019) (6)
Prostate cancer visibility on multiparametric magnetic resonance imaging: high Gleason grade and increased tumour volume are not the only important histopathological features (2020) (6)
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature. (2021) (6)
Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models (2021) (6)
15 Understanding patient attitudes towards BPH treatment: Results from the probe survey (2005) (6)
Conspicuity of prostate cancer on multiparametric magnetic resonance imaging: A cross‐disciplinary translational hypothesis (2020) (6)
Prostate motion modelling using biomechanically-trained deep neural networks on unstructured nodes (2020) (6)
855 HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) HEMIABLATION TRIAL IN LOCALISED UNILATERAL PROSTATE CANCER: INTERIM RESULTS (2009) (6)
THE EFFECTS OF THE TIME PERIOD BETWEEN BIOPSY AND DIFFUSION‐WEIGHTED MAGNETIC RESONANCE IMAGING ON CANCER STAGING IN LOCALIZED PROSTATE CANCER (2009) (6)
Prostate cancer measurements on serial MRI during active surveillance: it's time to be PRECISE. (2020) (6)
Prostate evaluation for clinically important disease: Sampling using image-guidance or not? (The PRECISION study, NCT02380027) (2018) (6)
BPH: a progressive disease of the ageing male (2002) (6)
"Don't Let the Perfect Be the Enemy of the Good": Time to Embrace Magnetic Resonance Imaging Before First Prostate Biopsy. (2018) (5)
Photodynamic therapy for primary prostate cancer - A pilot study using MTHPC (2004) (5)
Informed consent in clinical trials. Should be comprehensive... (1993) (5)
Clinical information system that enhances the use of resources in endoscopic prostatic procedures. (1992) (5)
MP53-03 TRANSPERINEAL MRI VISUALLY-TARGETED PROSTATE BIOPSIES COMPARED TO TEMPLATE MAPPING BIOPSY IN 534 MEN REQUIRING FURTHER RISK STRATIFICATION (2016) (5)
Comparison of Multiparametric Magnetic Resonance Imaging with Prostate-Specific Membrane Antigen Positron-Emission Tomography Imaging in Primary Prostate Cancer Diagnosis: A Systematic Review and Meta-Analysis (2022) (5)
Diagnostic Accuracy of Abbreviated Bi-Parametric MRI (a-bpMRI) for Prostate Cancer Detection and Screening: A Multi-Reader Study (2022) (5)
The challenging landscape of medical device approval in localized prostate cancer (2016) (5)
Prostate cancer risk stratification and cancer mapping-Template transperineal prostate mapping biopsies (2008) (5)
An exploratory study of dose escalation versus standard focal High Intensity Focused Ultrasound for treating non-metastatic prostate cancer. (2020) (5)
Tissue preservation may offer a harm-reduction strategy for men with early prostate cancer. (2012) (5)
Promoting the use of the PI-QUAL score for prostate MRI quality: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship (2022) (5)
Hormone therapy: a revolution in understanding prostate cancer. (2008) (5)
Renal tumouroids: challenges of manufacturing 3D cultures from patient derived primary cells (2022) (5)
VASCULAR-TARGETED PHOTODYNAMIC THERAPY IN ORGAN CONFINED PROSTATE CANCER -REPORT OF A NOVEL PHOTOSENSITISER (2006) (5)
Update from the ReIMAGINE Prostate Cancer Screening Study NCT04063566: Inviting Men for Prostate Cancer Screening Using Magnetic Resonance Imaging. (2021) (5)
Couch or crouch? Examining the prostate: a randomized study comparing the knee‐elbow and the left‐lateral position (2001) (5)
1364: The Effect on Voiding Patterns of a Self-Management Programme of Lifestyle and Behavioural Interventions for Men with Uncomplicated Lower Urinary Tract Symptoms (2004) (4)
Comparison of TRUS-Biopsy to Transperineal Template Mapping Biopsies Stratified by Multi-Parametric MRI Score within the PROMIS Trial. (2019) (4)
Multi-parametric magnetic resonance imaging in the diagnosis and characterization of prostate cancer prior to first biopsy in men at risk: The PROMIS study (2012) (4)
Conspicuity of cribriform prostate cancer on multiparametric magnetic resonance imaging: the jury is still out (2020) (4)
Quality of life research in urology (1999) (4)
ReIMAGINE Prostate Cancer Screening Study: protocol for a single-centre feasibility study inviting men for prostate cancer screening using MRI (2021) (4)
THE PART TRIAL ‐ A PHASE III STUDY COMPARING PARTIAL PROSTATE ABLATION VERSUS RADICAL PROSTATECTOMY (PART) IN INTERMEDIATE RISK PROSTATE CANCER – EARLY DATA FROM THE FEASIBILITY STUDY: PD56‐08 (2017) (4)
Exploring Patient Views and Acceptance of Multiparametric Magnetic Resonance Imaging for the Investigation of Suspected Prostate Cancer (the PACT Study): A Mixed-Methods Study Protocol (2020) (4)
Tookad soluble (WST-11) second generation vascular targeted photodynamic therapy (VTP) for prostate cancer: Safety and feasibility (2011) (4)
Tissue-Engineering the Fibrous Pancreatic Tumour Stroma Capsule in 3D Tumouroids to Demonstrate Paclitaxel Response (2021) (4)
Detailing sexual outcomes after treatment of localised prostate cancer with focal therapy using various energy sources: protocol for a mixed-methods study (2020) (4)
Detailing Sexual Outcomes After Focal Therapy for Localised Prostate Cancer: A Systematic Review and Meta-analysis. (2021) (4)
Tackling the quality agenda in surgery: taking comparative audit into the next century. (1999) (4)
MP18-08 FOCAL HIFU FOR TREATMENT OF LOCALISED PROSTATE CANCER: A MULTI-CENTRE REGISTRY EXPERIENCE (2016) (4)
133 A NEGATIVE MULTI-PARAMETRIC MRI CAN RULE OUT UP TO 97% OF CLINICALLY SIGNIFICANT PROSTATE CANCER (2011) (4)
Written consent is haphazard for minor urological procedures. (1997) (4)
Transrectal high intensity focused ultrasound in the treatment of localised prostate cancer-the first UK series (2008) (4)
Society for Social Medicine annual meeting 2000 (2000) (4)
IDENTIFY: The investigation and detection of urological neoplasia in patients referred with suspected urinary tract cancer: A multicentre cohort study (2020) (4)
Centralisation of cancer services vindicated (2010) (4)
1544: Management of Acute Urinary Retention: A Worldwide Comparison (2004) (4)
Progress in prostate cancer imaging. (2012) (4)
Seminoma or sarcoid? (1992) (4)
Role of MRI for the detection of prostate cancer (2021) (4)
AutoProstate: Towards Automated Reporting of Prostate MRI for Prostate Cancer Assessment Using Deep Learning (2021) (4)
Focal therapy for prostate cancer. Alternative treatment. (2014) (4)
A critical evaluation of visual proportion of Gleason 4 and maximum cancer core length quantified by histopathologists (2020) (4)
What to expect from a non-suspicious prostate MRI? A review. (2020) (4)
The prostate and benign prostatic hyperplasia (2004) (4)
[Focal therapy for prostate cancer: German version]. (2015) (4)
Symptomatic unilateral hydronephrosis: a late complication of aortobifemoral bypass graft surgery. (1997) (4)
Ethical dilemma - Retrieving semen from a dead patient - Utilitarianism in the absence of definitive guidelines (1998) (4)
Attitudes and experiences of human immunodeficiency Virus‐positive patients to surgery and surgeons (1992) (3)
Outcomes of the RAFT trial: robotic surgery after focal therapy (2021) (3)
717 Transperineal MRI-targeted biopsy versus transperineal template prostate mapping biopsy in the detection of localised radio-recurrent prostate cancer (2013) (3)
229 Eliciting preferences for benign prostatic hyperplasia medical treatment (2004) (3)
How will focal therapy fit in with existing treatments (2013) (3)
MP67-11 PROSTATE IMAGING (MULTI-PARAMETRIC MRI AND PROSTATE HISTOSCANNING™) COMPARED TO TRANSPERINEAL ULTRASOUND GUIDED BIOPSY FOR SIGNIFICANT PROSTATE CANCER RISK EVALUATION- THE PICTURE STUDY (2014) (3)
Interventional Techniques in Uro-oncology (2011) (3)
Evaluation of Proclarix, a prostate cancer risk score, used together with magnetic resonance imaging for the diagnosis of clinically significant prostate cancer. (2020) (3)
Partner's influence on patient preference for treatment in early prostate cancer (2004) (3)
Can quantitative analysis of multi-parametric MRI independently predict failure of focal salvage HIFU therapy in men with radio-recurrent prostate cancer? (2021) (3)
What urologists say they do for men with prostate cancer (1999) (3)
Acceptability and feasibility study of patient-specific ‘tumouroids’ as personalised treatment screening tools: Protocol for prospective tissue and data collection of participants with confirmed or suspected renal cell carcinoma (2019) (3)
Are men who are biopsied without prior prostate magnetic resonance imaging getting substandard care? (2015) (3)
Incidental prostate cancer diagnosed following a transurethral resection of the prostate: A national database analysis in England (2016) (3)
Evaluating variation in use of definitive therapy and risk-adjusted prostate cancer mortality in England and the USA (2015) (3)
What Burden of Prostate Cancer Can Radiologists Rule Out on Multiparametric Magnetic Resonance Imaging? A Sensitivity Analysis Based on Varying the Target Condition in Template Prostate Mapping Biopsies. (2015) (3)
Understanding patient and physician perceptions Editor's Choice of benign prostatic hyperplasia in Europe : The Prostate Research on Behaviour and Education (PROBE) Survey. Commentary (2008) (3)
Erratum: The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial (2016) (3)
Tumour growth rates of prostate cancer during active surveillance: is there a difference between MRI-visible low and intermediate-risk disease? (2021) (3)
Performance characteristics of multiparametric-MRI at a non-academic hospital using transperineal template mapping biopsy as a reference standard (2018) (3)
806 THE VALUE OF MAGNETIC RESONANCE IMAGING AND PSA IN DETECTING RECURRENCE AFTER HIGH INTENSITY FOCUSED ULTRASOUND (2009) (3)
From surgical audit to clinical effectiveness. (1998) (3)
POS-03.126: SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men (2007) (3)
Quality data - a prerequisite for assessing quality of care (2000) (3)
There Is No Longer a Role for Systematic Biopsies in Prostate Cancer Diagnosis (2022) (3)
1507: Acute Urinary Retention is Associated with an Increased Risk of Mortality (2007) (3)
Development data associated with effects of stiffness softening of 3D-TIPS elastomer nanohybrid scaffolds on tissue ingrowth, vascularization and inflammation in vivo (2019) (3)
Is the Toxicity of Salvage Prostatectomy Related to the Primary Prostate Cancer Therapy Received? (2020) (3)
1708: Response or not to Alfuzosin Treatment is Predictive of AUR and BPH Surgery (2005) (3)
Mapping Contemporary Biopsy Zones to Traditional Prostatic Anatomy: The Key to Understanding Relationships Between Prostate Cancer Topography, Magnetic Resonance Imaging Conspicuity, and Clinical Risk. (2021) (3)
Registration of preoperative MR to intraoperative ultrasound images for guiding minimally invasive prostate interventions (2007) (3)
Frequency volume charts should be used in men with lower urinary tract symptoms. (2005) (3)
Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study. (2022) (3)
Tissue Characterisation in Prostate Cancer Using a Novel Ultrasound Approach (2008) (3)
Diagnostic accuracy of the PROMIS study – Authors’ reply (2017) (3)
Management of Urological Cancers in Older People (2012) (3)
Re: Jarow et al.: Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop (Urology 2014;83:975-979). (2014) (3)
New standards in prostate biopsy. (2019) (2)
Derivation and comparison of site specific peripheral and transition zone quantitative DCE MRI logistic regression models for prostate cancer detection: does cancer location matter? (2013) (2)
2049 MAGNETIC RESONANCE IMAGE-GUIDED PROSTATE BIOPSY VERSUS TRANSPERINEAL TEMPLATE PROSTATE BIOPSY IN THE DIAGNOSIS OF CLINICALLY SIGNIFICANT PROSTATE CANCER (2012) (2)
Intra-prostatic injection of PRX302 to focally ablate clinically significant prostate cancer: An open label, phase 2a study (2017) (2)
Bi-parametric prostate MR image synthesis using pathology and sequence-conditioned stable diffusion (2023) (2)
INFORMATION BOOKLETS FOR MEN WITH LOCALIZED PROSTATE CANCER NEED TO BE IMPROVED (2006) (2)
Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy. (2022) (2)
Prostate radiofrequency ablation focal treatment (proRAFT): Results of a prospective development study for localised prostate cancer (2018) (2)
Will the attributes of multiparametric MRI permit the creation of a new approach to therapy? (2015) (2)
Which prostate cancers are overlooked by mpMRI? An analysis from PROMIS (2020) (2)
MP78-14 SITE OF DISEASE RECURRENCE FOLLOWING PROSTATE FOCAL THERAPY PREDICTS ONCOLOGICAL OUTCOME AFTER SALVAGE ROBOTIC ASSISTED RADICAL PROSTATECTOMY (2019) (2)
Prolonging survival in prostate cancer: chemotherapy will have an important role (2005) (2)
ABC of Prostate Cancer (2012) (2)
839 A prospective development study evaluating focal irreversible electroporation in men with localised prostate cancer: The NEAT trial (2016) (2)
The NHS patient information lottery: it is whom you see rather than what you need. (2000) (2)
high-intensity focused ultrasound for the treatment of prostate cancer (2006) (2)
THE SMARTTARGET BIOPSY TRIAL: A PROSPECTIVE PAIRED BLINDED TRIAL WITH RANDOMISATION TO COMPARE VISUAL‐ESTIMATION AND IMAGE‐FUSION TARGETED PROSTATE BIOPSIES: MP33‐20 (2017) (2)
1358: Muscarinic Receptor Sub-Types in the Human Prostate: Effects Upon Smooth Muscle Contractility and Localization Using Immunohistochemistry (2007) (2)
The Role of MRI in Active Surveillance (2012) (2)
Reply from Authors re: Giorgio Gandaglia, Alberto Briganti, Andrea Salonia, Francesco Montorsi. Excellent Erectile Function Recovery after Focal Therapy: Is This Enough? Eur Urol 2016;69:852-3: Focal Therapy Preserves Erectile Function in Men with Prostate Cancer. (2016) (2)
Focal HIFU for prostate cancer – Authors' reply (2012) (2)
Prostate-speci fi c antigen vs . magnetic resonance imaging parameters for assessing oncological outcomes after high intensity – focused ultrasound focal therapy for localized prostate cancer (2016) (2)
Investigating Men’s Perceptions on the Use Of Multiparametric MRI For The Diagnosis of Prostate Cancer (2019) (2)
Reply from authors re: Behfar ehdaie, shahrokh F. shariat. magnetic resonance imaging-targeted prostate biopsy: Back to the future. Eur urol 2013;63:141-2: What will it cost to target clinically relevant prostate cancer? (2013) (2)
Dynamic contrast-enhanced magnetic resonance imaging after vascular targeted photodynamic therapy with tookad in the primary treatment of prostate cancer (2007) (2)
Promoting the use of the PRECISE score for prostate MRI during active surveillance: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship (2022) (2)
An approach to surgical audit (2004) (2)
The role of multiparametric MRI in men with negative biopsy and elevated PSA - can it rule out clinically significant disease? (2012) (2)
What burden of prostate cancer can radiologists rule-out on multi-parametric MRI? An analysis based on template prostate mapping biopsies as the reference standard (2012) (2)
Contributing to medical research as a trainee: the problems and opportunities (2015) (2)
Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study (2021) (2)
THE ROLE OF TRANSPERINEAL TEMPLATE PROSTATE MAPPING BIOPSIES IN RISK-STRATIFYING MEN WITH LOCALISED PROSTATE CANCER (2008) (2)
A phase III study comparing partial prostate ablation versus radical prostatectomy (PART) in intermediate risk prostate cancer – initial data from the feasibility study (2017) (2)
SHOULD WE AIM FOR THE CENTRE OF AN MRI PROSTATE LESION? CORRELATION BETWEEN MPMRI AND 3‐DIMENSIONAL 5MM TRANSPERINEAL PROSTATE MAPPING BIOPSIES FROM THE PROMIS TRIAL: MP38‐07 (2017) (2)
MP-16.13: Vascular-Targeted Photodynamic Therapy Using WST11 in Patients with Localized Prostate Cancer (2009) (2)
SURGICAL MANAGEMENT AFTER ACTIVE SURVEILLANCE FOR LOW‐RISK PROSTATE CANCER: PATHOLOGICAL OUTCOMES COMPARED WITH MEN UNDERGOING IMMEDIATE TREATMENT (2011) (2)
18 EVALUATION OF HISTOSCANNING™ FOR THE DETECTION, LOCATION AND VOLUME ESTIMATION OF PROSTATE CANCER: RESULTS OF OPEN PHASE OF THE PHS-02 STUDY (2011) (2)
69 COMPARISON BETWEEN TRANSPERINEAL AND TRANSRECTAL BIOPSY FOR THE DETECTION OF PROSTATE CANCER TO GUIDE FOCAL THERAPY (2010) (2)
Photodynamic therapy for recurrent prostate cancer after radiotherapy: A pilot study (1998) (2)
The natural history of untreated prostate MRI lesions in an active surveillance prostate cancer population – 260 patient-years (2012) (2)
Light Density Index (LDI) is a Predictor of MRI and Biopsy Outcome for WST-11 (Tookad Soluble™) Mediated Vascular Targeted Photodynamic Therapy (VTP) in Focal Treatment of Localised Prostate Cancer (2010) (2)
Medium term oncological outcomes in a large cohort of men treated with either focal- or hemi-ablation with HIFU for primary localized prostate cancer (2019) (2)
Transrectal high intensity focused ultrasound in the treatment of primary localised prostate cancer (2008) (2)
Novel methods of treating early prostate cancer: cryotherapy and high‐intensity focused ultrasound (2010) (2)
Late toxicity described using patient reported outcomes measures (PROMS) in men treated with salvage radiation following primary high intensity focal ultrasound (HIFU) for localized prostate cancer. (2019) (2)
Prostate cancer and the human papilloma virus: causative association, role of vaccines, and the impact of the COVID-19 pandemic (2021) (2)
MP78-12 ROBOTIC ASSISTED RADICAL PROSTATECTOMY AFTER FOCAL THERAPY: ONCOLOGICAL AND FUNCTIONAL OUTCOMES (2019) (2)
“TREXIT 2020”: why the time to abandon transrectal prostate biopsy starts now (2020) (2)
urinary retention: database analysis Mortality in men admitted to hospital with acute (2008) (2)
The effect of prostatectomy on symptom reduction and quality of life (1996) (2)
The ability of MRI guided biopsy to detect clinically significant prostate cancer: a systematic review. (2012) (2)
Levels of Evidence (2007) (2)
1502: PSAWATCHTM - A 10 Minute, Quantitative PSA Assay on Stored Plasma (2006) (2)
Which Prostate Cancers are Undetected by Multiparametric Magnetic Resonance Imaging in Men with Previous Prostate Biopsy? An Analysis from the PICTURE Study (2021) (2)
Surgical Audit and the Evaluation of Surgery (2003) (2)
Dynamic contrast-enhanced magnetic resonance imaging after vascular-targeted photodynamic therapy (VTP) with Tookad (Padoporfin) in primary prostate cancer (2008) (2)
Re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 2018;74:84-91. (2019) (2)
Evaluation of functional outcomes following a second focal-HIFU in men with primary localised, non-metastatic prostate cancer; Results from the High Intensity Focused Ultrasound Evaluation and Assessment of Treatment (HEAT) Registry. (2020) (2)
Focal therapy for prostate cancer. Rationale, indications and selection. (2014) (2)
Intra-prostatic Cancer Recurrence following Radical Radiotherapy on Transperineal Template Mapping Biopsy: Implications for Focal Ablative Salvage Therapy. (2020) (2)
Behaviour modification and benign prostatic hyperplasia: replacement for medications (2010) (2)
Dropping the GAD – just a fad? The case for a simpler, quicker, safer and cheaper prostate magnetic resonance imaging (2019) (2)
225 FOCAL SALVAGE THERAPY COMPARED TO WHOLE-GLAND SALVAGE: A FEASIBILITY STUDY (2011) (2)
967 ULTRASOUND SPECTRAL INTERROGATION OF HISTOLOGICAL GRADE IN PROSTATE CANCER USING PROSTATE HISTOSCANNING (2011) (2)
Prototypical few-shot segmentation for cross-institution male pelvic structures with spatial registration (2022) (2)
How will focal therapy fit in with existing treatments? (2013) (2)
The Effect of Integrated Care Pathways on the Management of Men Undergoing Transurethral Prostatectomy (1997) (2)
Reply to S Eggener, M Gonzalgo and O Yossepowitch: ‘High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series’ (2009) (1)
THE ABILITY OF PROSTATE HISTOSCANNING™ TO IDENTIFY LOW VOLUME PROSTATE CANCER TUMOUR FOCI (2008) (1)
MP-08.19: Salvage HIFU effectively reduces PSA in patients with biochemical recurrence after attempted curative treatment for prostate cancer (2007) (1)
A protocol for the VISION study: An indiVidual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultraSound guided bIopsy in the detection of prOstate cancer (2022) (1)
Focal HIFU: Higher recurrence rate in treatment of anterior compared to posterior lesions in prostate cancer (2018) (1)
Computers in audit: servants or sirens? (1991) (1)
MP18-20 THE NANOKNIFE ELECTROPORATION ABLATION TRIAL (NEAT): A PROSPECTIVE DEVELOPMENT STUDY (2016) (1)
Does focal high-intensity focused ultrasound have a role in treating localized prostate cancer in the elderly? (2015) (1)
The patient with haemospermia. (2000) (1)
Siog (international society of geriatric oncology) localised prostate cancer guidelines proposals in senior adult men (2008) (1)
Patients ' information needs and surgeons ' factsheets on prostatectomy Closed response questions from the national prostatectomy audit (1)
DUTASTERIDE AND ACTIVE SURVEILLANCE IN PROSTATE CANCER: ARE VISIBLE LESIONS LESS CONSPICUOUS AT MAGNETIC RESONANCE IMAGING? A PILOT RANDOMIZED CONTROLLED TRIAL: PD55‐01 (2017) (1)
The Concept of the Index Lesion (2015) (1)
PD34-07 PSA FAILS TO PREDICT TREATMENT FAILURE IN FOCAL HIGH-INTENSITY FOCUSED ULTRASOUND THERAPY IN PROSTATE CANCER (2018) (1)
Relationship of prostate cancer topography and tumour conspicuity on multiparametric magnetic resonance imaging: a protocol for a systematic review and meta-analysis (2022) (1)
Prostate Cancer Undetected by mpMRI: Tumour Conspicuity is Reliant Upon Optimal Scan Timing and Quality. (2020) (1)
SELF-MANAGEMENT FOR MEN WITH UNCOMPLICATED LOWER URINARY TRACT SYMPTOMS: A RANDOMISED CONTROLLED TRIAL (2006) (1)
Prostate cancer heterogeneity: texture analysis score based on multiple MRI sequences for detection, stratification and selection of lesions at time of biopsy (2018) (1)
18F Choline PET/CT for assessing disease recurrence: Correlation with TRUS, MR template-guided prostate mapping biopsies (2012) (1)
Final Results of a Phase I/II Multicenter Trial of WST11 (TOOKAD ® Soluble) Vascular-Targeted Photodynamic Therapy (VTP) for Hemiablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Conducted in the United States (2017) (1)
Prostate Cancer Staging Tables—A Predictive Model for the UK (2008) (1)
22: The Impact of Hospital Provider Volume on the Outcome of Radical Cystectomy in the UK (2006) (1)
SIOG (INTERNATIONAL SOCIETY OF GERIATRIC ONCOLOGY) (2008) (1)
Distribution of prostate cancer on template prostate mapping (TPM) biopsies in men with low volume prostate cancer on transrectal ultrasound (TRUS) biopsies (2011) (1)
The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update (2015) (1)
TIME TO CYSTECTOMY - ITS INFLUENCE ON OVERALL SURVIVAL (2006) (1)
The ReIMAGINE Multimodal Warehouse: Using Artificial Intelligence for Accurate Risk Stratification of Prostate Cancer (2021) (1)
181 Can the findings of randomised clinical trials concerning the efficacy of prostate cancer therapy in men with early disease be replicated in national cancer registries (2013) (1)
Implications of using multi-parametric MRI as a triage test for men with a raised PSA - a real life practice study (2011) (1)
The use of trans-rectal high intensity focused ultrasound in salvage treatment for men who have failed primary radiation therapy of presumed organ confined prostate cancer (2007) (1)
844 PERFORMANCES OF TEMPLATE PROSTATE MAPPING (TPM) VERSUS TRANSRECTAL ULTRASOUND GUIDED (TRUS) BIOPSIES: AN ORIGINAL COMPUTER SIMULATION ON CYSTOPROSTECTOMY SPECIMENS (2011) (1)
MP-14.21 (2006) (1)
Geographic Variability, Time Trends and Association of Preoperative Magnetic Resonance Imaging with Surgical Outcomes for Elderly United States Men with Prostate Cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis (2022) (1)
Late Toxicity and Patient Reported Outcomes in Patients Treated With Salvage Radiation Following Primary High Intensity Focal Ultrasound for Localized Prostate Cancer (2017) (1)
426Improvement of sexual function with alfuzosin 10mg once daily is related to baseline LUTS and bother severity (2005) (1)
Prostate-specific membrane antigen positron emission tomography compared to multiparametric MRI for prostate cancer diagnosis: a protocol for a systematic review and meta-analysis (2021) (1)
Geographic Variability, Time Trends and Association of Preoperative MRI with Surgical Outcomes for Elderly US Men with Prostate Cancer: A SEER-Medicare Analysis. (2022) (1)
Acute Toxicity Rates in Patients Receiving Salvage Radical Prostate Irradiation Following Primary High Intensity Focused Ultrasound (HIFU) for Localised Prostate Cancer (2012) (1)
Urological Survey Urological Oncology: Prostate Cancer Re: Prostate Cancer Risk Inflation as a Consequence of Image-Targeted Biopsy of the Prostate: A Computer Simulation Study (2013) (1)
Spectrum of metastatic and nonmetastatic skeletal findings with dual-phase 18F-FECH PET/CT in patients with biochemical relapse of prostate cancer (2017) (1)
Translating cost‐utility modelling into the real world – the case of focal high‐intensity focussed ultrasound and active surveillance (2019) (1)
Doubling our precision of risk stratification in early prostate cancer: too good to be true? (2016) (1)
RELAPSE IN ACUTE URINARY RETENTION FOLLOWING ITS FIRST OCCURRENCE (2006) (1)
The relationship between volume and outcome in urological surgery (2004) (1)
928 PRE-BIOPSY MULTI-SEQUENCE MAGNETIC RESONANCE IMAGING OF THE PROSTATE IN THE DETECTION OF PROSTATE CANCER (2009) (1)
A CLINICAL EVALUATION OF THE OPTICAL CHARACTERISTICS OF THE PROSTATE IN MEN WITH PROSTATE CANCER (2006) (1)
Tissue Preservation: Active Surveillance and Focal Therapy as Complimentary Strategies (2018) (1)
The Concept of the Index Lesion (2015) (1)
Focal Photodynamic Therapy (2015) (1)
The effect of dutasteride on MRI-defined prostate cancer lesions: MAPPED (Magnetic resonance imaging in Primary Prostate Cancer after Exposure to Dutasteride) - a randomized placebo-controlled, double-blind clinical trial (2017) (1)
Towards a self-management programme for men with LUTS - the role of caffeinated drinks (2002) (1)
553 FIVE YEAR ONCOLOGICAL OUTCOMES FOLLOWING WHOLE-GLAND PRIMARY HIFU FROM THE UK INDEPENDENT HIFU REGISTRY (2013) (1)
Laparoscopic cholecystectomy. (1992) (1)
From the many to the few: changes in urological cancer surgery provision (2005) (1)
MP-08.20: Ablative salvage therapy following combination low dose rate brachytherapy and external beam radiation therapy is associated with higher levels of rectal toxicity (2007) (1)
Guidelines on BPH: an international comparison (2002) (1)
Re: Simpa S. Salami, Jeffrey J. Tosoian, Srinivas Nallandhighal, et al. Serial Molecular Profiling of Low-grade Prostate Cancer to Assess Tumor Upgrading: A Longitudinal Cohort Study. (2020) (1)
Prostate High-Intensity Focused Ultrasound (2010) (1)
707 HIGH INTENSITY FOCUSED ULTRASOUND (HIFU) FOR LOCALIZED PROSTATE CANCER (T1–2, NO, M0): INTRA-PROCEDURE DETERMINANTS OF BIOPSY PROVEN FAILURE USING THE SONOBLATE© 500 SYSTEM (2007) (1)
Irreversible tide of technological advancement? (2008) (1)
Focal HIFU for prostate cancer Reply (2012) (1)
Image quality assessment by overlapping task-specific and task-agnostic measures: application to prostate multiparametric MR images for cancer segmentation (2022) (1)
1305 POSTER SIOG (International Society of Geriatric Oncology) prostate cancer guidelines proposals in senior adult men (2007) (1)
Management of an Elevated PSA and Biopsy Strategies in the Large Prostate (2018) (1)
PD-01.10 (2006) (1)
Targeted biopsy of the prostate: improvement in detection of high-grade cancer, or the Will Rogers phenomenon? (2019) (1)
MP30-05 PROSTATE RADIOFREQUENCY ABLATION FOCAL TREATMENT (PRORAFT): RESULTS OF A PROSPECTIVE DEVELOPMENT STUDY FOR LOCALISED PROSTATE CANCER (2018) (1)
Has tailored, tissue‐selective tumour ablation in men with prostate cancer come of age? (2018) (1)
Deep Learning Based Long Term Mortality Prediction in the National Lung Screening Trial (2022) (1)
Predictive nomograms in prostate cancer — A European series (2003) (1)
Multiparametric magnetic resonance imaging in the diagnosis and characterisation of prostate cancer: The PROMIS study. (2012) (1)
Time to rethink PSA screening. (2011) (1)
Evidence-based medicine for urologists (2004) (1)
MP81-19 WHICH PROSTATE CANCERS ARE OVERLOOKED BY MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING? AN ANALYSIS FROM PROMIS (2020) (1)
MP62-03 HIGH-INTENSITY FOCUSSED ULTRASOUND IN THE TREATMENT OF LOCALISED PROSTATE CANCER: FOCAL SALVAGE TRANSITION RATES (2014) (1)
Are we ready for the new wave of focal therapy interventions for men with early prostate cancer? (2013) (1)
1370: Beneficial Effect of Alfuzosin 10mg Once Daily on Luts and Sexual Function: 18-months Results (2004) (1)
Visible disease at baseline accelerates time to exit from MRI-based active surveillance (2019) (1)
Assessment of Treatment Outcomes Following Prostate Cancer Therapy (2013) (1)
Diagnostic potential of radiological apical tumor involvement (2022) (1)
Quantification of Prostate Cancer Metabolism Using 3D Multiecho bSSFP and Hyperpolarized [1-13 C] Pyruvate: Metabolism Differs Between Tumors of the Same Gleason Grade. (2022) (1)
Correction: Corrigendum: Can we deliver randomized trials of focal therapy in prostate cancer? (2017) (1)
Histopathological basis of prostate cancer conspicuity on multiparametric magnetic resonance imaging: A systematic review and meta-analysis (2020) (1)
MP-18.15: Visually-directed primary HIFU for treating localised prostate cancer: determinants of PSA kinetics (2007) (1)
1352 RADIOLOGICAL PROGRESSION IN MEN WITH PROSTATE CANCER ON ACTIVE SURVEILLANCE (2013) (1)
Radical prostatectomy after vascular-targeted photodynamic therapy (VTP) with TOOKAD® : feasibility, early and intermediate results (2018) (1)
The impact of using voxel-level segmentation metrics on evaluating multifocal prostate cancer localisation (2022) (1)
Prolonged postoperative morbidity is an independent risk factor for reduced long-term survival (2013) (1)
PHOTODYNAMIC THERAPY (PDT) FOR PROSTATE CANCER: A PHASE I STUDY IN LOCALLY RECURRENT DISEASE AFTER RADIOTHERAPY (1999) (1)
18F-FECH PET/CT to Assess Clinically Significant Disease in Prostate Cancer: Correlation With Maximum and Total Cancer Core Length Obtained via MRI-Guided Template Mapping Biopsies. (2016) (1)
MRI as a follow up tool in active surveillance – results from an MRI-defined active surveillance cohort (387 men, median 5 year follow up) (2017) (1)
MRI and targeted biopsies compared to transperineal mapping biopsies for targeted ablation in recurrent prostate cancer after radiotherapy: Primary outcomes of the FORECAST trial. (2021) (1)
Dynamic variables: novel and perhaps better predictors of progression in benign prostatic hyperplasia (2006) (1)
Fortnightly review: Acute urinary retention in men: an age old problem (1999) (1)
Dual phase 18F-FDG PET/CT imaging in evaluation of "radio-recurrent" prostate cancer (2011) (1)
HAS THE DECLINE IN SURGICAL TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA RESULTED IN AN INCREASE IN THE INCIDENCE OF ACUTE URINARY RETENTION (2006) (1)
Urological emergencies. Part 1: Acute testicular pain, penile fracture and post-procedure emergencies (2010) (1)
1955. Propensity Score-Matched Comparison of Focal High Intensity Focused Ultrasound (HIFU) to Laparoscopic Radical Prostatectomy (LRP) for Clinically Significant Localised Prostate Cancer (2018) (1)
MP-03.05 Can Pre-Biopsy Multiparametric MRI Be Used to Detect Significant Prostate Cancer? (2011) (0)
Spectrum of metastatic and non-metastatic skeletal findings with dual-phase F-Fluoroethylcholine PET/CT in patients with biochemical relapse of prostate cancer (2017) (0)
Re : Prostate-Specific Antigen Decline after 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer (2016) (0)
Proclarix aids in resolving indeterminate multi-parametric magnetic resonance imaging for the improved diagnosis of prostate cancer (2022) (0)
The Urinary System (2002) (0)
Transrectal high-intensity focused ultrasound of the prostate-state-of-the-art treatment with the sonablate® 500 (2008) (0)
Comprar Focal Therapy In Prostate Cancer | Mark Emberton | 9781405196499 | Wiley (2011) (0)
THE IMPACT OF HOSPITAL PROVIDER VOLUME ON THE OUTCOME OF RADICAL NEPHRECTOMY (2006) (0)
138 Standards in reporting of MRI-targeted prostate biopsies (START): Recommendations from an international working party (2013) (0)
The changing prostate cancer pathway – new challenges, new pitfalls (2017) (0)
353 Report from an international consensus meeting on focal therapy (2014) (0)
Transperineal targeted prostate biopsy in the outpatients setting (2015) (0)
A hybrid CNN-RNN approach for survival analysis in a Lung Cancer Screening study (2023) (0)
941 TISSUE CHARACTERISATION (HISTOSCANNING) FOR DETECTION OF PROSTATE CANCER: INTERIM RESULTS FROM THE EXPLORATORY PHASE OF A PROSPECTIVE MULTI-CENTRE TRIAL (2009) (0)
Follow-Up of Men With PI-RADS 4 or 5 Abnormality on Prostate MRI and Non-Malignant Pathologic Findings on Initial Targeted Prostate Biopsy. (2020) (0)
Catheter associated urinary tract infection - can empirical treatment be right? (2004) (0)
Diagnostic accuracy of the PROMIS study Reply (2017) (0)
MP-03.10 Can Pre-biopsy Multi-parametric MRI Reduce the Number of TRUS Cores Required to Diagnose Prostate Cancer in an 'At-Risk' Population of Men? (2011) (0)
22 Patterns of prostate cancer on template prostate mapping biopsies in 291 men: Implications for focal therapy (2012) (0)
MP40-14 IS LOCAL ANAESTHETIC TRANSPERINEAL PROSTATE BIOPSY FEASIBLE AND ACCEPTABLE? A COMPARISON OF PATIENT EXPERIENCE UNDER LOCAL ANESTHETIC (LA) OR SEDATION. (2018) (0)
[Comparative characterization of different methods of perineum biopsy of the prostate]. (2011) (0)
Book review (1998) (0)
A semi-automated software program to assess the impact of second reads in prostate MRI for equivocal lesions: results from a UK tertiary referral centre. (2023) (0)
Prostate Imaging Compared to Transperineal Ultrasound-guided biopsy for significant prostate cancer Risk Evaluation (PICTURE): a prospective cohort validating study assessing Prostate HistoScanning (2018) (0)
Functional outcomes from the Robotic surgery After Focal Therapy (RAFT) clinical trial (2020) (0)
MP30-10 HIFU DOSE ESCALATION LEADS TO FEWER RECURRENCES IN FOLLOWING FOCAL HIFU IN PROSTATE CANCER (2018) (0)
When thinking of initiating medical therapy for lower urinary tract symptoms, ask about cataracts (2005) (0)
UP-02.153 An International Multi-Centre Phase II Prospective Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound (Sonablate 500) for Localized Prostate Cancer (2011) (0)
218 Association of level of suspicion of prostate cancer on multi-parametric MRI with detection rate of prostate cancer (2013) (0)
MP46-19 detailing sexual outcomes after focal therapy for localised prostate cancer: a systematic review and meta-analysis (2021) (0)
Can TRUS Power Doppler Predict the Preservation of Erectile Function in HIFU Treatment of Localised Prostate Cancer? — A Preliminary Study (2006) (0)
Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging. (2023) (0)
Masking the scrotal problem in surgery. (2009) (0)
Dosimetry Modeling for Focal LDR Prostate Brachytherapy (2013) (0)
POD-08.02: Prostate biopsy indications: practice patterns and the potential role of PCA3 (2007) (0)
Prostate cancer segmentation from MRI by a multistream fusion encoder. (2023) (0)
When Looking at Quality, What Should We be Measuring: Structure, Process or Outcome? (1998) (0)
324 Is PSA density a useful biomarker in the age of frequent imaging for prostate cancer (2015) (0)
Morbidity associated with redo-HIFU of localized prostate cancer (2013) (0)
810 Do prophylactic antibiotics on urinary catheter withdrawal stop urinary tract infection? A pilot randomised double-blind placebo-controlled trial (2004) (0)
533 PERFORMANCE CHARACTERISTICS OF DIFFERENT TRANSRECTAL (TRB) AND TRANSPERINEAL MAPPING PROSTATE BIOPSY (TPB) STRATEGIES: A SIMULATION ON 96 CYSTOPROSTATECTOMY SPECIMENS (CPTS) (2011) (0)
Prostate cancer and the human papilloma virus: causative association, role of vaccines, and the impact of the COVID-19 pandemic (2021) (0)
Satellite communication on laparoscopic surgery (1991) (0)
738 The concordance between volume hotspot and grade hotspot: A 3D reconstructive model using pathology outputs from the PROMIS multicenter trial (2014) (0)
Is perfect the enemy of good? Weighing the evidence for biparametric MRI in prostate cancer. (2021) (0)
Biparametric MRI detects the aggressive molecular features of prostate cancer (2020) (0)
The feasibility of eliciting patient perceived outcome in men following prostatectomy. (1997) (0)
MRI in active surveillance: a critical review (2018) (0)
1092 EVALUATION OF HISTOSCANNING™ FOR THE DETECTION, LOCATION AND VOLUME ESTIMATION OF PROSTATE CANCER: RESULTS OF OPEN PHASE OF THE PHS–02 STUDY (2011) (0)
Image‐Guided Magnetic Thermoseed Navigation and Tumor Ablation Using a Magnetic Resonance Imaging System (Adv. Sci. 12/2022) (2022) (0)
MRI and targeted biopsies compared to transperineal mapping biopsies for targeted ablation in recurrent prostate cancer after radiotherapy: Primary outcomes of the FORECAST trial (2021) (0)
Foreword (2012) (0)
PD34-04 BIOPSY OUTCOMES AND PATTERNS OF PROSTATE CANCER GRADE PROGRESSION IN THE PCM301 RANDOMIZED TRIAL OF VASCULAR TARGETED PHOTODYNAMIC THERAPY AND ACTIVE SURVEILLANCE: IMPLICATIONS FOR FOCAL THERAPY (2018) (0)
Regarding: 'High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series' Reply (2009) (0)
Validation of the needle targeting accuracy of a MRI/TRUS- image-guided system for transperineal prostate cancer biopsy (2015) (0)
Comment on: "A prospective randomized controlled trial comparing target prostate biopsy alone approach vs. target plus standard in naïve patients with positive mpMri". (2023) (0)
Levels of evidence: the box within the abstract (2008) (0)
Cholinergic control of prostate contractility mediated through smooth muscle M3 receptors (2007) (0)
LBA23 FOUR-YEAR FOLLOW-UP OF A PHASE-3 PROSPECTIVE RANDOMIZED TRIAL OF VASCULAR-TARGETED PHOTOTHERAPY VERSUS ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER. (2018) (0)
THE IMPACT OF HOSPITAL PROVIDER VOLUME ON THE OUTCOME OF CYSTECTOMY IN THE UK (2006) (0)
Are men who are biopsied without a prior prostate MRI getting sub-standard care? (2015) (0)
PICTURE: Prostate Imaging Compared to Transperineal Ultrasound guided biopsy for significant prostate cancer Risk Evaluation. A trial descriptor (2012) (0)
Focal Therapies for Localized Prostate Cancer (2013) (0)
The natural history of prostate cancer on MRI: lessons from an active surveillance cohort (2018) (0)
MP-21.13: Accuracy of Multi-sequence Magnetic Resonance Imaging of Radio-recurrent Prostate Cancer (2009) (0)
MP55-06 FOCAL ABLATIVE SALVAGE THERAPY FOR RADIO-RECURRENT PROSTATE CANCER: 6 YEAR ONCOLOGICAL AND SAFETY OUTCOMES (2022) (0)
712 MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING (MP-MRI) AND LOCALISATION OF SIGNIFICANT PROSTATE CANCER: CAN IT BE USED AS A TRIAGE TOOL? (2010) (0)
The quality of studies addressing diagnostic accuracy of flow rate testing in men with LUTS (2002) (0)
A MULTIVARIATE LOGISTIC REGRESSION INVESTIGATING WHICH FACTORS INFLUENCE DETECTION OF CLINICALLY SIGNIFICANT CANCER BY MRI‐TARGETED PROSTATE BIOPSY: PD43‐06 (2017) (0)
385: Temporal Trends in Radical Prostatectomy: UK Hospital Episode Statistics Data 1995-2001 (2004) (0)
585 Focal therapy targeted to the index lesion in multifocal prostate cancer: A prospective development study (2013) (0)
mpMRI-visible prostate cancer is enriched with genomic hallmarks of poor prognosis: A bioinformatic analysis (2020) (0)
Retrospective evaluation of Proclarix as a companion to mpMRI for the detection of clinically significant prostate cancer (2021) (0)
PSA density and clinical outcome in MRI-based active surveillance for prostate cancer: A joint longitudinal-survival analysis (2021) (0)
195Radical nephrectomy practice in england between 1995 and 2002 (2005) (0)
Intussusception in infants. (1992) (0)
Baseline characteristics in an MRI-based active surveillance cohort: Association with clinical and histological outcomes (2018) (0)
Waiting for surgery (2002) (0)
MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years (2018) (0)
348 ALFUZOSIN 10MG ONCE DAILY IS EFFECTIVE ON LUTS AND NOCTURIA IRRESPECTIVE OF AGE AND SHOWS A LOW INCIDENCE OF BPH PROGRESSION EVENTS, EVEN IN ENLARGED PROSTATES (2007) (0)
1356 BIOCHEMICAL VERSUS IMAGING PARAMETERS FOR ASSESSING ONCOLOGICAL OUTCOMES FOLLOWING FOCAL THERAPY FOR LOCALISED PROSTATE CANCER (2013) (0)
267 Radiological progression in men with prostate cancer on active surveillance (2013) (0)
Exploiting the Tumour Microenvironment in Order to Optimise Sonodynamic Therapy for Cancer (2020) (0)
FINGER-PRICK PSA TESTING. DO PSA LEVELS IN CAPILLARY CORRELATE WITH PSA LEVELS IN VENOUS BLOOD? (2006) (0)
PD34-01 COMPARISON OF RADICAL TREATMENT AND MORTALITY IN PATIENTS WITH NON-METASTATIC PROSTATE CANCER IN ENGLAND AND USA (2014) (0)
747 Incidence of benign prostatic hyperplasia clinical progression over time in the combination of avodart and tamsulosin (CombAT) study (2012) (0)
Comment on: Focal Therapy for Localized Prostate Cancer : A Critical Appraisal of Rationale and Modalities. Authors' reply (2008) (0)
The Postoperative Morbititu Survery was Validated adn Used to Descrive Morbidity after Major Surgery (2007) (0)
The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses. (2022) (0)
Prostatic high-resolution micro-ultrasound: an attractive step-forward in the management of prostate cancer patients. (2022) (0)
MP67-19 MORPHOLOGICAL ASSESSMENT OF ANTERIOR LESIONS ON PROSTATE MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING. (2014) (0)
The relationship between percentage PSA reduction and rate of failure after focal therapy for prostate cancer (2020) (0)
Transrectal ultrasound guided biopsy: effect on natural history of multi-parametric MRI signal and derived quantitative parameters (2014) (0)
Abstract 2415: Polygenic risk-tailored screening for prostate cancer: A cost-effectiveness analysis (2019) (0)
The early detection of cancer. (1966) (0)
Contemporary practice, however, bears little resemblance to those fi rst treated cases. Foreword. (2012) (0)
Optimising the diagnosis of prostate cancer in the era of multi-parametric magnetic resonance imaging: a cost-effectiveness analysis based on the PROMIS study : How to optimise the diagnosis of prostate cancer (2017) (0)
Electroporation Ablation Trial ( NEAT ) : a prospective development study investigating focal irreversible electroporation for localised prostate cancer (2021) (0)
Decision fusion of 3D convolutional neural networks to triage patients with suspected prostate cancer using volumetric biparametric MRI (2020) (0)
Template transperineal prostate mapping biopsies prostate cancer risk stratification and cancer localization (2009) (0)
Mens experience of lower urinary tract symptoms. An investigation of bother (2004) (0)
ReIMAGINE Prostate Cancer Risk: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood, urine and imaging for biomarker analyses (2023) (0)
Prostate Cancer IRE Study (PRIS): A Randomized Controlled Trial Comparing Focal Therapy to Radical Treatment in Localized Prostate Cancer. (2023) (0)
Intratumoural (IT) evolutionary landscape of high-risk prostate cancer and outcome: The PROGENY (PROstate cancer GENomic heterogeneitY) study of genomic and immune parameters. (2020) (0)
1466 COULD USE OF MRI IN MEN REFERRED FOR RISK OF PROSTATE CANCER RESULT IN A REDUCTION OF BIOPSY RELATED MORBIDITY WHEN COMPARED TO THE ERSPC AND PCPT RISK CALCULATORS FOR DECISION TO BIOPSY (2013) (0)
Pelvic floor muscle training: when the source of prostate pain is not the prostate gland (2002) (0)
International society of geriatric oncology (SIOG) proposal of guidelines for advanced prostate cancer in senior adults (2008) (0)
MP30-08 COMPARISON OF TRUS-BIOPSY TO TRANSPERINEAL TEMPLATE MAPPING BIOPSIES STRATIFIED BY MRI SCORE WITHIN THE PROMIS TRIAL (2019) (0)
'Cognitive' MRI-guided TRUS biopsy targeting - does it require specialist radiological expertise? (2012) (0)
Energies for Focal Ablation: Photodynamic Therapy (2011) (0)
LBA03-07 IMPERIAL PROSTATE-4 COMPARATIVE HEALTHCARE RESEARCH OUTCOMES OF NOVEL SURGERY IN PROSTATE CANCER (IP4-CHRONOS): EARLY FEASIBILITY, SAFETY AND FUNCTIONAL OUTCOMES FROM A PILOT RCT (2023) (0)
Behavioural interventions in the management of the overactive bladder. (2017) (0)
846Beneficial effects of alfuzosin iomg once daily on lower urinary tract symptoms, quality of life and sexual function: A 2-year experience in BPH patient's in real life practice (2005) (0)
A Systematic Review and Meta-Analysis of Patient Race, Ethnicity, Socioeconomic Status and Educational Attainment in Prostate Cancer Treatment Randomised Trials – Is the Evidence Base Applicable to the General Patient Population? (2022) (0)
Comparing biparametric to multiparametric MRI in the diagnosis of clinically significant prostate cancer in biopsy-naive men (PRIME): a prospective, international, multicentre, non-inferiority within-patient, diagnostic yield trial protocol (2023) (0)
UP-2.161: Focal High Intensity Focused Ultrasound (HIFU) Therapy in the Treatment of Localised Prostate Cancer: Early Results of a Phase II Trial (2009) (0)
Using data from two prospective randomized clinical trials to model morbidity of vascular targeted phototherapy (VTP), active surveillance (AS) and radical prostatectomy (RP) (2019) (0)
820 The importance of a visible lesion in imaging based active surveillance for prostate cancer (2015) (0)
PV-0038: Multivariable model development for mortality after total salvage Iodine-125 prostate brachytherapy (2016) (0)
ULTRASOUND BASED TISSUE CHARACTERISATION (HISTOSCANNING) IMAGING FOR PROSTATE CANCER: INTERIM RESULTS FROM THE EXPLORATORY PHASE OF A PROSPECTIVE MULTI-CENTRE TRIAL (2009) (0)
342 Earlier initiation of treatment with the dual 5α reductase inhibitor dutasteride reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic hyperplasia (2004) (0)
Reply (2009) (0)
Re: Jochen Walz. The "PROMIS" of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? Eur Urol 2018;73:31-2. (2018) (0)
Patterns of prostate cancer on template prostate mapping biopsies in 291 men: Implications for focal therapy (2012) (0)
Results of Tookad (r) soluble vascular targeted photodynamic therapy (VTP) for low risk localized prostate cancer (PCM 201/PCM 203). (2011) (0)
Lower Urinary Tract Symptoms (2019) (0)
MP26-07 WHICH PROSTATE CANCERS ARE UNDETECTED BY MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING IN MEN WITH PRIOR PROSTATE BIOPSY? AN ANALYSIS FROM THE PICTURE STUDY (2021) (0)
212: Validity of Charlson Comorbidity Scores Based on ICD-10 Administrative Data to Assess Comorbidity in Patients Undergoing Radical Urological Cancer Surgery in England (2005) (0)
104 WHO OPENED THE PROSTATE CANCER PANDORA'S BOX? A HISTORICAL EVALUATION OF THE DIAGNOSTIC PATHWAY IN PROSTATE CANCER (2011) (0)
Editorial Comment. (2016) (0)
A new quality control scoring system for multiparametric MRI of the prostate from the PRECISION trial (2020) (0)
SP-0020: Is there a role for focal treatment in prostate cancer?: The urologist point of view (2014) (0)
Reply to TS Clark: ‘High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series’ (2009) (0)
Patient perspectives of multiparametric magnetic resonance imaging-directed prostate cancer diagnosis: A prospective systematic mixed-methods study (the PACT study) (2021) (0)
MP55-01 CANCER CONTROL OUTCOMES FOLLOWING FOCAL THERAPY USING HIFU IN 1,379 MEN WITH NON-METASTATIC PROSTATE CANCER: A MULTI-INSTITUTE 15-YEAR EXPERIENCE (2022) (0)
Is there a skew loose in your clinical database (2001) (0)
Evaluation of Outcomes following Focal Ablative Therapy for Treatment of Localised Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-year Experience. (2023) (0)
1546: Bothersomeness of Luts Differs in Europe, Middle-East, Latin America, Asia and Canada (2004) (0)
Self-management benefits men with lower urinary tract symptoms: a randomised controlled trial (2007) (0)
PD50-02 NATURAL HISTORY OF PROSTATE CANCER ON ACTIVE SURVEILLANCE: STRATIFICATION BY MRI USING THE PRECISE RECOMMENDATIONS IN A UK COHORT OVER 11 YEARS (2019) (0)
Reply from Authors re: Giorgio Gandaglia, Alberto Briganti, Andrea Salonia, Francesco Montorsi. Excellent Erectile Function Recovery after Focal (2016) (0)
The assessment of men with lower urinary tract symptoms using frequency volume charts (2004) (0)
MP78-10 A COMPARISON OF CANCER CONTROL OUTCOMES AT 5 YEARS OF FOCAL THERAPY (USING HIFU & CRYOTHERAPY) TO RADICAL PROSTATECTOMY FOR CLINICALLY SIGNIFICANT NON-METASTATIC PROSTATE CANCER: PROPENSITY SCORE-MATCHED ANALYSIS (2019) (0)
1354: Bother and IPSS Worsening Under Treatment and History of AUR, are the Most Important Risk Factors for AUR/BPH Surgery (2004) (0)
Regional differences in the clinical profile of 3,230 men consulting for luts in Europe, Russia, Middle-East, Latin America and Asia (2003) (0)
MAPPED: Magnetic resonance imaging in Primary Prostate cancer after Exposure to Dutasteride: Reduction in tumour volume at 6 months in men on active surveillance for prostate cancer (2014) (0)
Treating coexistent benign prostatic hyperplasia/lower urinary tract symptoms and erectile dysfunction in the aging male (2007) (0)
Cancer control outcomes following focal therapy using HIFU in 1,829 men with non-metastatic prostate cancer treated over 15 years (2021) (0)
Histopathological features of prostate cancer conspicuity on multiparametric MRI: protocol for a systematic review and meta-analysis (2020) (0)
156 MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING IN RADIO-RECURRENT PROSTATE CANCER (2010) (0)
MP46-05 IRREVERSIBLE ELECTROPORATION OF THE PROSTATE: PREDICTING THE LIKELIHOOD OF AVOIDING RADICAL THERAPY IN A MODERATE TO HIGH RISK COHORT OF MEN (2021) (0)
528 RE-CLASSIFICATION STRATEGIES IN MEN WITH LOW RISK PROSTATE CANCER: TRUS GUIDED BIOPSY VERSUS TEMPLATE PROSTATE MAPPING (2011) (0)
MP56-18 MRI-CALCULATED PSA DENSITY AND CLINICALLY SIGNIFICANT CANCER IN THE BIOPSY-NAIVE PROSTATE (2020) (0)
MP-13.03 Does Repeat Focal Ablation using High Intensity Focused Ultrasound (Sonablate 500) Compromise Morbidity or Genito-Urinary Functional Outcome in Men with Localized Prostate Cancer? (2011) (0)
Tumor Topography for Diagnosis of Prostate Cancer. (2021) (0)
Interobserver reproducibility of the Prostate Imaging Quality (PI-QUAL) score for prostate MRI quality (2021) (0)
Combining mpMRI sequences for the diagnosis of prostate cancer – the value of adding diffusion and contrast enhancement to T2W on 3Tesla: Outcomes from the PICTURE trial (2016) (0)
1251 THE START CONSORTIUM RECOMMENDATIONS FOR THE REPORTING OF MRI–TARGETED PROSTATE BIOPSIES (2013) (0)
615 IS THERE A RELATIONSHIP BETWEEN VOLUME OF PROSTATE CANCER TUMOUR FOCI AND GLEASON SCORES (2009) (0)
A BS TR AC T MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis (2018) (0)
Phenotypic appearances of prostate utilizing PET-MRI and PET-CT with 68Ga-PSMA, radiolabelled choline and 68Ga-DOTATATE (2018) (0)
Sexual dysfunction and prostate cancer therapy (2016) (0)
MP48-15 EVALUATING THE CLINICAL UTILITY OF TRANSPERINEAL TEMPLATE PROSTATE MAPPING BIOPSY (2015) (0)
ALFUZOSIN 10MG ONCE DAILY ADMINISTERED FOR 3 YEARS IS ASSOCIATED WITH A LOW INCIDENCE OF LUTS/BPH PROGRESSION EVENTS (2006) (0)
841 Medium term outcomes following focal HIFU for the treatment of non-metastatic prostate cancer: A UK registry analysis of 625 cases (2016) (0)
Novel Therapies for Localized Prostate Cancer (2014) (0)
1215 THE ABILITY OF MRI GUIDED BIOPSY TO DETECT CLINICALLY SIGNIFICANT PROSTATE CANCER: A SYSTEMATIC REVIEW (2012) (0)
Focal or Multifocal Therapy in Prostate Cancer: New Technologies and Strategies (2015) (0)
Protocol for a MULTI-centre feasibility study to assess the use of 99mTc-sestaMIBI SPECT/CT in the diagnosis of kidney tumours (MULTI-MIBI study) (2023) (0)
Will imaging help us with the problem of over‐diagnosis and over‐treatment in men with prostate cancer? (2009) (0)
The Good Will Scenario (2017) (0)
821 Magnetic resonance image-guided prostate biopsy versus transperineal template prostate biopsy in the diagnosis of clinically significant prostate cancer (2012) (0)
Re: Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes? (2020) (0)
BPH: Combination therapy—a strategy for BPH-related progression (2010) (0)
PD50-05 VISIBLE DISEASE AT BASELINE ACCELERATES TIME TO EXIT FROM MRI-BASED ACTIVE SURVEILLANCE (2019) (0)
A TRAINING COURSE FOR THE UROLOGIST IMPROVES THEIR ABILITY TO INTERPRET CLINICALLY SIGNIFICANT PROSTATE CANCER ON MULTIPARAMETRIC MRI: MP51‐12 (2017) (0)
Bile duct injury following laparoscopic cholecystectomy. (1992) (0)
Co morbidity and hypertensive medication did not affect tolerability of alfuzosin 10mg once a day (2004) (0)
INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer (2016) (0)
The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy (2017) (0)
URINARY INCONTINENCE AFTER PROSTATE CANCER Image guided diagnosis and treatment to prevent incontinence after radical prostatectomy (2012) (0)
Dutasteride of its Use in the Management of Prostate Disorders (2008) (0)
Focal ablative salvage therapy for radio-recurrent prostate cancer: 6 year oncological and safety outcomes (2021) (0)
150 Bothersomeness of lower urinary tract symptoms differs in Europe, Middle-East, Latin America, Asia and Canada (2004) (0)
MP21-08 FEASIBILITY OF ESTABLISHING RENAL CANCER PATIENT-SPECIFIC ‘TUMOUROIDS’ AS PERSONALISED TREATMENT SCREENING TOOLS (2019) (0)
819 Does dutasteride make MRI visible lesions less conspicuous in men on active surveillance for prostate cancer? A pilot randomised controlled trial (2015) (0)
Distinct immunohistochemical findings for common biomarkers in malignant and adjacent benign prostate: A study on needle biopsy microarrays derived from mpMRI-characterized tissue (2018) (0)
Bother and IPSS worsening under treatment and urinary retention history are the most important risk factors for AUR/BPH surgery (2004) (0)
Seven‐Year Outcomes Following HIFU in Patients with Localized Prostate Cancer (2007) (0)
1707: Beneficial Effects of Alfuzosin 10mg OD on Luts, Quality of Life and Sexual Function: A 2-Year Experience in BPH Patients in Real Life Practice (2005) (0)
Do antibiotics on urinary catheter withdrawal prevent the incidence of urinary tract infection? A pilot randomised double-blind placebo-controlled study (2003) (0)
Self mngement for men with lower urinry trct symptoms: rndomised controlled tri l (2007) (0)
Men's Health (2000) (0)
1701: Improvement of Sexual Function with Alfuzosin 10MG Once Daily is Related to Baseline Luts and Bother Severity (2005) (0)
84 TRIAGE MRI FOLLOWED BY MRI-TARGETED BIOPSY FOR MEN WITH PROSTATE CANCER: A DECISION ANALYSIS (2013) (0)
UP-2.160: Treating Unilateral Localised Prostate Cancer with Hemi-Ablation High Intensity Focused Ultrasound (HIFU): Results of a NCRN-Approved Phase II Focal Therapy Clinical Trial (2009) (0)
Advancing research capacity within British urology – a joint BAUS and RCS England two-day workshop (2015) (0)
MRI index lesions in the cancerous prostate: How do they differ from false positive phenotypes? Lessons from the PROMIS study (2020) (0)
MRI-targeted biopsy versus systematic biopsy in the detection of prostate cancer: a systematic review and meta-analysis (2019) (0)
What happens if focal therapy fails? A comparative effectiveness study of salvage treatment for recurrent prostate cancer (2022) (0)
Sexual dysfunction in patients with LUTS suggestive of BPH (2002) (0)
Is focal ablation as effective as hemi-ablation? analysis of treatment patterns over 12 years from a high volume centre for focal therapy (2020) (0)
MP18-02 DEVELOPMENT AND INTERNAL VALIDATION OF A MULTIVARIABLE PREDICTION MODEL FOR BIOCHEMICAL FAILURE AFTER FOCAL SALVAGE HIGH INTENSITY FOCUSED ULTRASOUND FOR LOCALLY RECURRENT PROSTATE CANCER: PRESENTATION OF A RISK SCORE FOR INDIVIDUAL PATIENT PROGNOSIS. (2016) (0)
1369: Co-Morbidity and Hypertensive Medication do not Affect Tolerability of Alfuzosin 10MG Once Daily (2004) (0)
The need for advanced analytical methods for big data in urology: A first application from the ReIMAGINE risk study (2023) (0)
The management of radiologically indeterminate MRI signal in men at risk of prostate cancer (2017) (0)
353 Prostate HistoScanning for the detection, localization and volume estimation of prostate cancer- PHS02 blind phase results (2013) (0)
Focal Salvage HIFU for Radiorecurrent Prostate Cancer: Disease control outcomes (2014) (0)
Magnetic Resonance Imaging Follow-up of Targeted Biopsy-negative Prostate Lesions. (2023) (0)
360 A prospective analysis of the effects of focal therapy for prostate cancer on erectile function (2014) (0)
A historical evaluation of the changes in prostate cancer diagnosis over eight decades (2011) (0)
High-intensity Focused Ultrasound of the Prostate (2018) (0)
The use of conjoint analysis to assess patients' preferences in the treatment of organ confined and locally advanced prostate cancer (2001) (0)
Acute urinary retention: defining the need and timing for pressure-flow studies - Editorial comment (2001) (0)
847Response or not to alfuzosin treatment is predictive of acute urinary retention and BPH surgery (2005) (0)
Should prophylactic antibiotics be given on urinary catheter withdrawal? A randomized double-blind placebo-controlled trial (2003) (0)
Data of a stiffness softening mechanism effect on proliferation and differentiation of a human bone marrow derived mesenchymal stem cell line towards the chondrogenic and osteogenic lineages (2018) (0)
Focal Therapy in Prostate Cancer: Future Directions (2012) (0)
DECIDING THE FUTURE OF BRITISH UROLOGY (2006) (0)
MP38-10 MULTI-INSTITUTIONAL VALIDATION OF THE PRECISE CRITERIA ON PROSTATE MRI DURING ACTIVE SURVEILLANCE (2023) (0)
108 TEMPLATE TRANSPERINEAL PROSTATE MAPPING BIOPSIES FOR PROSTATE CANCER RISK STRATIFICATION AND CANCER LOCALIZATION (2010) (0)
Survival After Postoperative Morbidity: A Longitudinal Observational Cohort Study (2015) (0)
MP-14.22 (2006) (0)
THE PROBLEM OF OVERTREATMENT (2010) (0)
New Technologies in Urology (2010) (0)
Multiparametric magnetic resonance imaging in the diagnosis and characterisation of prostate cancer: The PROMIS study. (2012) (0)
30: Time to Cystectomy - its Influence on Overall Survival (2006) (0)
Exploring the risk-reward balance in focal therapy for prostate cancer—a contribution to the debate (2019) (0)
The British Prostate Group Autumn Meeting, 10–11 September 2001, Royal College of Surgeons, Lincoln's Inn Fields, London, UK (2002) (0)
226 Bother and IPSS worsening under treatment and history of AUR, are the most important risk factors for AUR/BPH surgery (2004) (0)
Abstract LB-269: Engineering a vascularized 3Din vitromodel of cancer progression (2016) (0)
Cost-Effectiveness of Diagnosis: from Tests to Long-Term Outcomes and Costs (2017) (0)
Evidence based management of male lower urinary tract symptoms: A contemporary update. (2016) (0)
Urinary retention and obstructive uropathy (2004) (0)
Prostate cancer topography and tumour conspicuity on multiparametric magnetic resonance imaging: A systematic review and meta-analysis (2021) (0)
THE EVALUATION OF PATIENT INFORMATION BOOKLETS FOR LOCALISED PROSTATE CANCER (2006) (0)
Stiffness Softening: Thermoresponsive Stiffness Softening of Hierarchically Porous Nanohybrid Membranes Promotes Niches for Mesenchymal Stem Cell Differentiation (Adv. Healthcare Mater. 10/2019) (2019) (0)
Title of review article: The role of the multi-parametric MRI in the diagnosis of prostate cancer in biopsy-naïve men. Author(s): (2017) (0)
361 A pilot study assessing the toxicity profile of irreversible electroporation in the focal treatment of prostate cancer (2014) (0)
Prostate cancer intra-tumoral heterogeneity: Correlation between clinical parameters, mpMRI and biomarkers (2017) (0)
MP-13.19 Clinically Significant Prostate Cancer Is Present Anteriorly in Nearly Fifty-Percent of Men Classified as Presumed Low-Risk on Diagnostic TRUS Biopsies (2011) (0)
Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial. (2022) (0)
233 RADICAL PROSTATE CANCER THERAPY IS ASSOCIATED WITH A SURVIVAL BENEFIT IN THE OLDER MAN (2013) (0)
A randomized controlled trial to investigate magnetic resonance imaging-targeted biopsy as an alternative diagnostic strategy to transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer. (2015) (0)
An Evaluation of Hemi‐Ablation Therapy Using High‐Intensity Focused Ultrasound in the Treatment of Localized Adenocarcinoma of the Prostate (2007) (0)
HIGH‐INTENSITY FOCUSED ULTRASOUND FOR LOCALIZED PROSTATE CANCER: INITIAL EXPERIENCE WITH A 2‐YEAR FOLLOW‐UP (2009) (0)
Reply by Authors. (2020) (0)
INTRA‐PROSTATIC PRX302 FOCAL THERAPY IN TREATING CLINICALLY SIGNIFICANT LOW‐INTERMEDIATE PROSTATE CANCER: AN OPEN LABEL, PROOF‐OF‐CONCEPT STUDY: MP70‐15 (2017) (0)
Minimally invasive therapies in prostate and renal cancer (2010) (0)
Active Surveillance, Focal Therapy, and the Future (2012) (0)
A Short History of the Modern Outcomes Movement (1997) (0)
Determinants of failure in men undergoing salvage high intensity focused ultrasound (sonoblate 500TM) following failed external beam radiotherapy for primary prostate cancer (2011) (0)
Addition of Anterior Cores in Transrectal Prostate Biopsies Cannot Replace Performance of Template-Mapping Biopsies in Detection of Prostate Cancer: A Simulation on Cystoprostatectomy Specimens (2010) (0)
Performance Characteristics of Prostate Biopsy Strategies in a Simulation: Transrectal Ultrasound (TRUS) versus Template Prostate Mapping (TPB) (2010) (0)
Patient Perspectives and Understanding of MRI-Directed Prostate Cancer Diagnosis. (2021) (0)
Development and external validation of a novel model to identify patients with equivocal lesion at multiparametric MRI who can avoid prostate biopsy (2019) (0)
893 TRIFECTA OUTCOMES AFTER WHOLE-GLAND HIGH INTENSITY FOCUSED ULTRASOUND FOR THE TREATMENT OF LOCALISED PROSTATE CANCER: A REGISTRY-BASED ANALYSIS (2011) (0)
1470 CAN MRI PREDICT UPGRADING OF TRUS BIOPSY RESULTS AT MORE DEFINITIVE HISTOLOGY (2013) (0)
Porous Nanohybrid Membranes Promotes Niches (2019) (0)
Non-rigid Medical Image Registration using Physics-informed Neural Networks (2023) (0)
Patient information and the outcome of prostatectomy (1996) (0)
1042 Active surveillance in men with pure Gleason 6 confirmed on template prostate mapping biopsies (2015) (0)
The 10th anniversary of the research fellowship scheme of the RCS (2005) (0)
Management of AUR a worldwide comparison (2004) (0)
The importance of lesion conspicuity in prostate cancer risk assessment (2022) (0)
Evaluating Focal Therapy: Future Perspectives (2011) (0)
Acute urinary retention in men - Management is more complex issue than was described - Reply (1999) (0)
Focal Therapy in Prostate Cancer: Ahmed/Focal Therapy in Prostate Cancer (2011) (0)
Feasibility of establishing renal cancer patient-specific ‘tumouroids’ as personalised treatment screening tools (2019) (0)
593 UK hospital and surgeon volumes for urological cancer care and surgeons' views on minimum volume thresholds (2004) (0)
CN6: MEN'S PREFERENCES FOR THE CONSERVATIVE MANAGEMENT OF NON-METASTATIC PROSTATE CANCER: THE USE OF CONJOINT ANALYSIS (2001) (0)
Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study. (2020) (0)
2015 Journal of Urology Consultants. (2016) (0)
Catheter psychosis. (1993) (0)
Role of Imaging as an Adjunct or Replacement for Biopsy: European Experience (2013) (0)
PD25-01 FUNCTIONAL OUTCOMES OF VASCULAR TARGETED PHOTOTHERAPY (VTP), ACTIVE SURVEILLANCE (AS) AND RADICAL PROSTATECTOMY (RP): MORBIDITY MODELLING USING DATA FROM TWO PROSPECTIVE RANDOMIZED CLINICAL TRIALS (2019) (0)
Template Transperineal Prostate Mapping Biopsies in Determining Optimal Standard Care and Suitability for Focal Therapy (2010) (0)
Surgeons' views on volume thresholds for urological cancer care (2003) (0)
Focal Therapy of Prostate Cancer Using High Intensity Focused Ultrasound—Interim Results from Two Phase II Trials (2010) (0)
THE IMPACT OF AGE AND COMORBID DISEASE ON THE OUTCOME OF RADICAL CYSTECTOMY (2006) (0)
MP45-15 A PROSPECTIVE ANALYSIS OF THE EFFECTS OF FOCAL THERAPY FOR PROSTATE CANCER ON ERECTILE FUNCTION FROM A COMBINED ANALYSIS OF 3 PROSPECTIVE TRIALS (2014) (0)
High‐Intensity Focused Ultrasound (2011) (0)
Poster Session 8: Clinical Governance: Consent and Communication (2003) (0)
599 Temporal trends in radical cystectomy: UK hospital episode statistics data 1995–2001 (2004) (0)
The role of percentage of PSA reduction after focal therapy using high intensity focused ultrasound for primary localized prostate cancer. Results from a large multinstitutional series (2020) (0)
Behavioural approaches are helpful in overactive bladder (2003) (0)
Prostate HistoScanning - computer aided transrectal ultrasound imaging for prostate cancer diagnosis: interim results from a prospective multi-centre trial (2009) (0)
Selective Minimally Invasive Therapy in Older Patients for Localized Prostate Cancer: A Way to Mitigate Harm and Retain Benefit? (2013) (0)
Best practice in the management of BPH (2004) (0)
CORRELATION OF MPMRI CONTOURS WITH 3‐DIMENSIONAL 5MM TRANSPERINEAL PROSTATE MAPPING BIOPSY WITHIN THE PROMIS TRIAL PILOT: WHAT MARGINS ARE REQUIRED?: MP70‐02 (2017) (0)
To see or not to see — what renders prostate cancer visible? (2019) (0)
OC-0064: A prediction model for biochemical failure after salvage Iodine-125 prostate brachytherapy (2016) (0)
MP77-20 PREDICTION OF SIGNIFICANT PROSTATE CANCER IN BIOPSY-NAÏVE MEN: EXTERNAL VALIDATION OF A NOVEL RISK MODEL COMBINING MRI AND CLINICAL PARAMETERS (2018) (0)
384Circumcision in England between 1995/1996 and 1999/2000 (2005) (0)
1135: The Role of Dynamic Contrast Enhanced MRI (DCE MRI) in Refining the Outcome of High Intensity Focused Ultrasound (HIFU) for Localized Prostate Cancer (2006) (0)
PD50-07 TIME TRENDS AND GEOGRAPHIC VARIABILITY IN PREOPERATIVE MRI FOR PROSTATE CANCER AND ITS ASSOCIATION WITH SURGICAL MARGIN STATUS IN THE UNITED STATES (2021) (0)
prostatectomy . audit of process and outcome of The feasibility and cost of a large multicentre (0)
Targeted Increases in Per-operative Global Blood Flow to Explicit Goals and Surgical Mortality (2001) (0)
MP23-20 LOW PSA DENSITY AT BASELINE IS ASSOCIATED WITH PROLONGED MRI-BASED ACTIVE SURVEILLANCE FOR GLEASON 6 PROSTATE CANCER (2020) (0)
Natural history of prostate cancer on active surveillance: Stratification by MRI using the PRECISE recommendations in a UK cohort over 11 years (2019) (0)
MP78-05 MEDIUM TERM ONCOLOGICAL OUTCOMES IN A LARGE COHORT OF MEN TREATED WITH EITHER FOCAL- OR HEMI-ABALTION WITH HIFU FOR PRIMARY LOCALIZED PROSTATE CANCER (2019) (0)
MP56-04 MRI INDEX LESIONS IN THE CANCEROUS PROSTATE: HOW DO THEY DIFFER FROM FALSE POSITIVE PHENOTYPES? LESSONS FROM THE PROMIS STUDY (2020) (0)
Oncological outcomes of 356 patients undergoing salvage focal ablative HIFU or cryotherapy following radiation failure. (2020) (0)
Minimally Invasive Technologies in the Treatment of Renal and Prostate Cancer (2010) (0)
Ultra-fast biparametric MRI for prostate cancer detection (2021) (0)
Effect of short term treatment with finasteride on prostatic microvascularity with BPH (2002) (0)
Pushing the Limits with Nanoknife®: A Promising New Technology in Localised Prostate Cancer Management (2015) (0)
Evaluation of a self-management intervention for men with lower urinary tract symptoms (2006) (0)
PD22-01 THE GLIMPSE STUDY: GLOBAL VARIATION IN THE QUALITY OF MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING OF THE PROSTATE FROM THE PRIME TRIAL (2023) (0)
Karim O, Rao A, Emberton M, Cochrane D, Partridge M, Edwards P, Walker I, Davidson I. (2007) (0)
Four-year Follow-up of a Phase-3 Prospective Randomized Trial of Partial Gland Ablation with Vascular- Targeted Phototherapy versus Active Surveillance for Low-risk Prostate Cancer (2018) (0)
Cambridge Handbook of Psychology, Health and Medicine: Urinary tract symptoms (2007) (0)
MP53-05 MULTI-PARAMETRIC MRI FOR DETECTION OF RADIO-RECURRENT PROSTATE CANCER: WHAT CONSTITUTES AN OPTIMAL DATASET? (2014) (0)
Abstract 3523: MRI-first screening for prostate cancer: A benefit-harm and cost-effectiveness analysis (2020) (0)
Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging–targeted Biopsy. Eur Urol 2020;7:739-747 (2021) (0)
951 The PICTURE Study – prostate imaging (multi-parametric MRI and Prostate HistoScanning™) compared to transperineal ultrasound guided biopsy for significant prostate cancer risk evaluation (2014) (0)
Technical Notes and Tips: Masking the Scrotal Problem in Surgery (2009) (0)
MP24-18 SYSTEMATIC REVIEW AND META-ANALYSIS OF SIGNIFICANT CANCER DETECTION BY MRI-TARGETED BIOPSY COMPARED TO SYSTEMATIC BIOPSY (2019) (0)
Why does multiparametric magnetic resonance imaging miss clinically significant prostate cancer? A systematic review of the literature (2017) (0)
851 SONABLATE® INTERNATIONAL HIFU REGISTRY (SIHR): A TOOL FOR DYNAMIC QUALITY IMPROVEMENT (2009) (0)
MP73-08 FOCAL ABLATIVE SALVAGE THERAPY FOR RADIO-RECURRENT PROSTATE CANCER: A 10 YEAR EXPERIENCE OF ONCOLOGICAL AND SAFETY OUTCOMES IN 276 PATIENTS (2023) (0)
Prostate Cancer: Localized IXMP83-01 TRANSPERINEAL MRI-TARGETED BIOPSY VERSUS TRANSPERINEAL TEMPLATE PROSTATE MAPPING BIOPSY IN THE DETECTION OF LOCALISED RADIO-RECURRENT PROSTATE CANCER (2015) (0)
ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement (2021) (0)
Image guided diagnosis and treatment to prevent incontinence after radical prostatectomy (2012) (0)
The role of angiotensin-converting enzyme (ACE) inhibitors in delaying the progression of metastatic hormone relapsed prostate cancer (2003) (0)
Clinical Decision-Making in Listing Patients for a Transurethral Resection of the Prostate (2008) (0)
P042 Late toxicity in patients treated with salvage radical radiotherapy following primary High-Intensity Focal Ultrasound (HIFU) for localized prostate cancer (2014) (0)
Title: Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity matched study (2021) (0)
The CADMUS trial: A paired cohort, blinded study comparing multiparametric ultrasound targeted biopsies with multiparametric MRI targeted biopsies in the detection of clinically significant prostate cancer. (2021) (0)
Global variation in the quality of multiparametric magnetic resonance imaging of the prostate from the PRIMEtrial (the glimpse study) (2023) (0)
MR-directed selective HIFU therapy of prostate cancer using a TRUS guidance platform (2012) (0)
Focal salvage high-intensity focused ultrasound ablation therapy (Sonoblate 500TM) following failed external beam radiation therapy to the prostate (2011) (0)
Natural history of prostate cancer during active surveillance on MRI using the PRECISE criteria: A multicentre study (2023) (0)
Identifying the Index Lesion (2013) (0)
Clinical outcomes associated with prostate cancer conspicuity on biparametric and multiparametric MRI: a protocol for a systematic review and meta-analysis of biochemical recurrence following radical prostatectomy (2021) (0)
HIFU focal therapy for localised prostate cancer (2017) (0)
Multiparametric MRI in the diagnosis of prostate cancer: a validation study of the European Consensus Meeting Risk Scoring System (2013) (0)
The Role of mp-MRI in the Detection of Prostate Cancer (2012) (0)
Whole-gland salvage therapy using high-intensity focused ultrasound (sonoblate 500tm) for presumed local recurrence following external beam radiation therapy to the prostate (2011) (0)
POD-07.06 Inter-observer Variability in the Interpretation of HistoScanning™ Characterisation of Prostate Cancer (2011) (0)
Focal Therapy Using High Intensity Focused Ultrasound for Intermediate and High Risk Prostate Cancer: A Registry-Based Cohort Analysis (2010) (0)
Micro-ultrasound vs. MRI for prostate cancer diagnosis: Considerations to address (Re: Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer, CUAJ, Jan 2021). (2021) (0)
642 UNDETECTED HIGH-GRADE PROSTATE CANCERS IN THE REDUCTION BY DUTASTERIDE OF CLINICAL PROGRESSION EVENTS (REDUCE) STUDY USING PSA MONITORING GUIDELINES (2011) (0)
Robotic assisted radical prostatectomy after focal therapy: Oncological and functional outcomes (2019) (0)
An end to the phenomenon of ‘upgrading’ in early prostate cancer? (2017) (0)
Proceedings of the Anaesthetic Research Society Meeting Royal College of Anaesthetists, London, UK, December 13–14, 2012 (2013) (0)
Photodynamic Therapy for Early Prostate Cancer (2013) (0)
2213 RESULTS OF MRI TARGETED, VISUALLY REGISTERED, TRANS-RECTAL ULTRASOUND GUIDED PROSTATE BIOPSY (2013) (0)
845Alfuzosin 10 mg once daily is well tolerated in elderly men with cardiovascular co-morbidities (2005) (0)
Temporal trends in radical prostatectomy: UK hospital episode statistics, 1995-2001 (2004) (0)
1344 WHICH ABLATIVE STRATEGY IN LOCALIZED PROSTATE CANCER IS BEST FOR ERECTILE FUNCTION PRESERVATION (2013) (0)
1355: The Relationship between Frequency-Volume Chart Data and the International Prostate Symptom Score (IPSS) in Men with Lower Urinary Tract Symptoms (2006) (0)
384: Indicators of Health Care Expenditures in Patients with Lower Urinary Tract Symptoms (LUTS) Treated with Alfuzosin 10 mg OD (2004) (0)
1444 WHAT BURDEN OF PROSTATE CANCER IS MISSED BY A NEGATIVE MULTI-PARAMETRIC MRI? AN ANALYSIS BASED ON TEMPLATE PROSTATE MAPPING AS THE REFERENCE STANDARD (2012) (0)
Combined surgical audit by microcomputer involving units in four health regions. (1992) (0)
1361: Earlier Initiation of Treatment With the Dual 5 α Reductase Inhibitor Dutasteride Reduces the Risk of Acute Urinary Retention and Surgical Intervention in Men With Benign Prostatic Hyperplasia (2004) (0)
Yet to Come 2 Brachytherapy for prostate cancer (2016) (0)
Nanotechnology for the Urologist (2010) (0)
Hospital volume: how does high volume lead to better quality? (2017) (0)
PD34-08 DETERMINANTS OF ERECTILE DYSFUNCTION FOLLOWING FOCAL ABLATIVE THERAPY FOR LOCALISED PROSTATE CANCER. (2018) (0)
Time to evaluate focal therapy (2010) (0)
Clinical practice guidelines for men with luts. To what extent can they be trusted (2002) (0)
Photodynamic Therapy – A Potential Candidate for Focal Treatment of Organ-Confined Prostate Cancer ? (2006) (0)
PROSTATE RADIOFREQUENCY ABLATION FOCAL TREATMENT (PRORAFT): INTERIM RESULTS OF A PROSPECTIVE DEVELOPMENT STUDY: MP70‐18 (2017) (0)
2214 PROSTATE HISTOSCANNING FOR THE DETECTION OF CLINICALLY SIGNIFICANT PROSTATE CANCER - RESULTS FROM THE BLIND PHASE OF THE MULTICENTRE EUROPEAN PHS02 STUDY (2013) (0)
– Prostate Cancer The Role of Focal Therapy in the Management of Localised Prostate Cancer : A Systematic Review (2014) (0)
352 Co-morbidity and antihypertensive medication do not affect tolerability of Alfuzosin 10mg once daily (2004) (0)
498 The UCL PICTURE trial: A prospective cohort validating study evaluating the accuracy of multi-parametric MRI and prostate HistoScanning compared to transperineal template mapping biopsies in patients requiring risk stratification after prior transrectal prostate biopsy (2016) (0)
Comparison of biparametric and multiparametric magnetic resonance imaging for prostate cancer detection: an 8-month update on the PRIME Study (NCT04571840) (2023) (0)
Beneficial effect of alfuzosin 10mg OD daily on LUTS and sexual function (2004) (0)
Patterns of microbial resistance in catheter associated urinary tract infection (2002) (0)
MP36-16 DEVELOPMENT AND EXTERNAL VALIDATION OF A NOVEL MODEL TO IDENTIFY PATIENTS WITH EQUIVOCAL LESION AT MULTIPARAMETRIC MRI WHO CAN AVOID PROSTATE BIOPSY (2019) (0)
Corrigendum to "Magnetic Resonance Imaging and targeted biopsies compared to transperineal mapping biopsies prior to salvage focal therapy/ablation in localised and metastatic recurrent prostate cancer after radiotherapy. Primary Outcomes from the FORECAST Trial" [Eur Urol 2022;81(6):598-605]. (2023) (0)
MP30-11 PREDICTORS OF POOR FUNCTIONAL OUTCOMES AFTER FOCAL HIGH INTENSITY FOCUSSED ULTRASOUND (HIFU) (2018) (0)
PD60-11 DISTINCT PROTEIN EXPRESSION PATTERNS FOR COMMON BIOMARKERS IN MALIGNANT AND ADJACENT BENIGN PROSTATE TISSUE: AN IMMUNOHISTOCHEMICAL STUDY ON NEEDLE BIOPSY MICROARRAYS DERIVED FROM AN IMAGING-BASED PATIENT COHORT (2018) (0)
PD60-02 DISCOVERY AND VALIDATION OF A NOVEL FLUID BIOMARKER FOR THE DIAGNOSIS AND RISK STRATIFICATION OF PROSTATE CANCER (2018) (0)
Association of radical prostate cancer therapy with a survival benefit in the older man. (2013) (0)
Focal Therapy in Prostate Cancer: HIFU (2012) (0)
MP-11.19: Can dynamic contrast enhanced magnetic resonance imaging of the prostate reliably detect prostate cancer prior to TRUS biopsy? (2007) (0)
Standardisation of Focal Therapy Protocols (2013) (0)
180 PROGRESSION OF BENIGN PROSTATIC HYPERPLASIA: SYSTEMATIC REVIEW OF THE PLACEBO ARMS OF TRIALS (2007) (0)
PSAWATCH™ - A 10-MINUTE, QUANTITATIVE PSA ASSAY ON STORED PLASMA (2006) (0)
Reply to Francesco Montorsi, Giorgio Gandaglia, Alberto Briganti's Letter to the Editor, re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review, Meta-analysis. Eur (2019) (0)
Interventional Techniques in Uro-Oncology: Arya/Interventional Techniques in Uro-Oncology (2011) (0)
Re: Quantitation of hypoechoic lesions for the prediction and Gleason grading of prostate cancer: a prospective study (2019) (0)
Exploration of patient trust on the use of multiparametric magnetic resonance imaging for the diagnosis of prostate cancer: Qualitative interim analysis of the PACT study (2021) (0)
Combined PCA3 and pre-biopsy multi-parametric MRI in men with a raised PSA (2011) (0)
The CADMUS trial: A paired cohort, blinded study comparing multiparametric ultrasound targeted biopsies with multiparametric MRI targeted biopsies in the detection of clinically significant prostate cancer (2021) (0)
[Significance of the number of biopsy specimens from the prostate gland for adequate clinical appraisal of neoplasia]. (2010) (0)
Post-cholecystectomy symptoms after laparoscopic cholecystectomy. (1994) (0)

This paper list is powered by the following services:

Other Resources About Mark Emberton

What Schools Are Affiliated With Mark Emberton?

Mark Emberton is affiliated with the following schools:

Mark Emberton's Academic­Influence.com Rankings

Why Is Mark Emberton Influential?

Mark Emberton's Published Works

Published Works

Other Resources About Mark Emberton

What Schools Are Affiliated With Mark Emberton?

Mark Emberton's AcademicInfluence.com Rankings